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RESUMO 
Hoje em dia, o cancro é um dos maiores problemas a nível de saúde pública por todo o mundo. A 
radioterapia tem assumido uma importância cada vez maior, no que concerne a tratamentos do foro 
oncológico. O objetivo principal da radioterapia prende-se com irradiar o tecido do tumor com uma elevada 
dose, poupando o tecido normal e saudável circundante o máximo possível, de modo a limitar possíveis 
complicações durante o tratamento do paciente. De entre os métodos de radioterapia mais utilizados, 
destacam-se a radioterapia de intensidade modulada (IMRT), e uma nova técnica que constitui uma forma 
avançada de IMRT, a terapia de arco volumétrico (VMAT). Ao contrário dos tratamentos de IMRT, durante 
os quais o acelerador (LINAC) roda diversas vezes em torno do paciente, ou faz paragens e recomeços 
repetidos de forma a irradiar o tumor de diferentes ângulos, nos tratamentos VMAT, a dose é entregue ao 
tumor por inteiro, durante uma única rotação de 360 ° (tipicamente em menos de dois minutos). Com o 
crescente uso das técnicas de IMRT e VMAT em ambiente clínico e, consequentemente, com o crescente 
aumento da complexidade dos planos de tratamento e das doses prescritas (aumento do número de planos 
hipofracionados e de dose única), a necessidade de procedimentos de controlo de qualidade (QA) tem vindo 
a aumentar. Por esta razão, os procedimentos de QA rotineiros já não são suficientes e, de modo a detetar 
possíveis erros, tornou-se necessário desenvolver novos procedimentos de QA. 
 
Os procedimentos de QA incluem a verificação pré-tratamento, onde o procedimento de QA é feito 
antes do tratamento, aquando a irradiação de um fantoma, e a verificação in vivo, onde o procedimento de 
QA é feito durante o tratamento, aquando a irradiação do paciente. Por questões de segurança, a verificação 
pré-tratamento é o procedimento de QA mais frequente na maioria das clínicas de radioterapia, permitindo 
a deteção de erros de forma precoce, dado esta ser feita antes de sujeitar o paciente ao tratamento de 
radioterapia. No caso da Fundação Champalimaud, a verificação pré-tratamento é feita rotineiramente com 
recurso a um fantoma constituído por díodos designado ArcCHECK. No entanto, esta solução apresenta 
grandes desvantagens dado o tempo despendido no procedimento de QA, bem como o peso e a baixa 
resolução do fantoma em questão. Por essa razão, a possibilidade de introdução e utilização de um 
dispositivo de imagem portal (EPID) na clínica, que permita otimizar todo o processo de verificação de pré-
tratamento, tem vindo a ser estudada.  
 
Os EPIDs foram concebidos e desenvolvidos originalmente com o propósito de verificação da 
posição do paciente durantes as sessões de radioterapia. No entanto, há mais de uma década, os EPIDs 
começaram a ser utilizados em contexto clínico, como procedimentos de QA de verificação pré-tratamento 
no caso de planos de IMRT e VMAT. Atualmente, os EPIDs constituem uma ferramenta avançada de 
tecnologia digital, que permite melhorias na localização da região alvo, mantendo a eficiência clínica. A 
dosimetria portal apresenta de facto grandes vantagens, nomeadamente, a aquisição rápida de imagens, a 
alta resolução, e o potencial para introdução de verificação in vivo e verificação de dose a 3D. 
 
Aquando a verificação pré-tratamento de planos IMRT e VMAT, é necessário proceder à 
verificação de dose, de modo a evitar a subdose do volume alvo, ou a sobredose dos tecidos normais. Assim, 
diferentes métodos de verificação de dose que permitem a comparação entre as distribuições de dose (a de 
referência e a medida) têm vindo a ser desenvolvidos e implementados na prática clínica. Um dos métodos 
de verificação de dose mais utilizado hoje em dia é o método de avaliação gama ou análise gama. Este 
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método constitui uma ferramenta quantitativa de comparação de distribuições de dose, e permite determinar 
se os pontos de dose comparados passam ou falham o teste de comparação – é dito que os pontos de dose 
comparados passam o teste de comparação se o gama for igual ou menor que 1, sendo que, por oposição, os 
pontos de dose comparados falham o teste de comparação se o gama for maior que 1. 
 
O presente projeto teve como objetivo principal, a implementação clínica e rotineira do EPID para 
verificação pré-tratamento, com vista à substituição dos procedimentos de QA realizados com recurso ao 
ArcCHECK. Para tal, diferentes estudos foram conduzidos em diferentes LINAC (TrueBeam™ e Edge™). 
Inicialmente, compararam-se os resultados obtidos aquando a utilização da solução de dosimetria portal 
desenvolvida pela Varian para verificação pré-tratamento, com os resultados obtidos aquando da utilização 
do ArcCHECK, para ambos os LINAC. No sentido de testar e comparar a sensibilidade de ambos os 
sistemas (EPID e ArcCHECK) durante a verificação pré-tratamento, foram também levados a cabo estudos 
com vista à introdução de erros nos planos dos pacientes. Finalmente, de forma análoga, introduziram-se 
diferentes tipos de erro no plano de um paciente, de forma a avaliar os efeitos destes ao nível dos órgãos de 
risco (OARs). 
 
No que respeita aos primeiros testes, estabelecendo um critério de análise gama com uma diferença 
de dose de 3%, e uma distância de concordância (DTA) de 3mm, concluiu-se, para o LINAC TrueBeam™, 
que os resultados obtidos aquando da verificação pré-tratamento eram melhores quando se usava o 
ArcCHECK, e piores quando se usava o EPID. Já para o LINAC Edge™, o contrário foi verificado no 
sentido em que os resultados obtidos aquando da verificação pré-tratamento se revelaram melhores para o 
EPID, e piores para o ArcCHECK. Esta discrepância pode ser explicada tendo em conta os diferentes EPID 
incorporados em cada um dos diferentes LINAC, sendo que o LINAC Edge™ tem provavelmente um 
melhor EPID (mais recente) que o LINAC TrueBeam™. Aquando os testes de introdução de diferentes 
tipos de erros (MUs, posição do MLC – aleaórios e sistemáticos-, e ângulo do colimador) nos ficheiros 
XML contendo os planos dos pacientes, para uma análise gama 3 %/3 mm, concluiu-se que o EPID era 
sensível aos diferentes tipos de erros dado que, quanto maior a magnitude do erro introduzido, pior a 
irradiação, e, consequentemente, piores os resultados obtidos. Em comparação com o ArcCHECK, o EPID 
demonstrou-se igualmente sensível, permitindo, no entanto, resultados mais coerentes. Finalmente, a 
influência dos diferentes tipos de erros introduzidos nos órgãos em risco foi de encontro ao esperado na 
medida em que, quanto maior a magnitude do erro introduzido, maiores os valores de diferença obtidos a 
nível de volumes e, consequentemente, menores os valores de gama, e maiores os efeitos nos órgãos em 
questão. 
 
No final, a análise de resultados demonstrou e veio confirmar as claras vantagens do EPID face ao 
ArcCHECK, dado que este permitiu melhores resultados, demonstrando-se, ao mesmo tempo, mais sensível 
a erros introduzidos nos planos dos pacientes. No entanto, mais estudos devem ser conduzidos no sentido 
de testar mais casos clínicos com tumores presentes em diferentes localizações e diferentes fracionamentos. 
Em todo o caso, devido aos resultados promissores obtidos durante este projeto, pela primeira vez na 
Fundação Champalimaud, o EPID começou a ser usado de forma rotineira para verificação pré-tratamento 
num dos LINAC disponíveis (LINAC Edge™), substituindo os antigos e pouco vantajosos procedimentos 
de QA feitos com recurso ao ArcCHECK. Esta nova prática clínica e, ao fim ao cabo, mudança de 
paradigma, apenas vem encorajar a continuação dos estudos para implementação de procedimentos de QA 
com o EPID para verificação pré-tratamento nos restantes LINAC disponíveis na Fundação Champalimaud, 
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bem como estimular a implementação de procedimentos de QA, também com recurso ao EPID, mas para 
verificação in vivo. 
 
Palavras-Chave: Tumor; Controlo de Qualidade; Dosimetria Pré-tratamento; Dosimetria EPID; 
Análise Gama. 
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ABSTRACT 
Nowadays, cancer is one of the major public health problems around the world. Radiotherapy is one 
of the most widely used cancer treatment method, and, among the most commonly used radiotherapy 
methods, are intensity modulated radiotherapy (IMRT), and a novel radiation technique called volumetric 
modulated arc therapy (VMAT), which is an advanced form of IMRT. With the increased use of IMRT and 
VMAT, and, consequently, increasing in treatment plans complexity, as well as higher dose prescriptions, 
the demand for patient-specific quality assurance (QA) procedures has increased, in order to avoid major 
errors. Thus, recommended QA procedures might no longer be sufficient and new procedures are necessary 
to detect possible errors.  
 
Patient-specific quality assurance includes both pre-treatment verification, where the QA procedure 
is done before the treatment, with a phantom, and in vivo verification, where the QA procedure is done 
during the treatment, with the patient. For a question of safety, in clinical practice, pre-treatment patient-
specific QA procedures are more common, once they allow the early detection of errors, prior to the 
radiotherapy treatment. At Champalimaud Foundation, the pre-treatment patient-specific QA is performed 
routinely using a cylindrical detector array called ArcCHECK. However, due the cumbersome and low-
resolution of ArcCHECK, Electronic Portal Image Device (EPID) has been studied. EPIDs provide an 
advanced tool with digital technology to improve target localization and maintain clinical efficiency. EPID 
dosimetry has a lot of advantages such as fast image acquisition, high resolution, digital format, and potential 
for in vivo measurements and 3D dose verification, which make it a very promising tool. 
 
The main goal of this project was to examine the clinical introduction of EPID for pre-treatment 
dosimetry, in order to replace ArcCHECK QA measurements and bring into the clinic the routinely use of 
EPID to perform QA measurements. For that, different studies were conducted on both TrueBeam™ and 
Edge™ LINAC, where the performance of the portal dosimetry solution (Portal Dosimetry software 
developed by Varian) for pre-treatment patient-specific QA of IMRT and VMAT plans was compared with 
ArcCHECK. Moreover, errors were introduced in the patient plans in order to study and compare the 
sensitivity of both EPID ArcCHECK during pre-treatment patient-specific QA, and evaluate the effects of 
the different types of error in the organs at risk.  
 
Regarding the first tests, for a gamma analysis with a dose-difference criterion of 3 % and distance-
to-agreement (DTA) of 3 mm, on the TrueBeam™ LINAC, we have obtained better results with 
ArcCHECK, while, on the Edge™ LINAC, we have obtained better results with EPID. This discrepancy 
can be explained by the different a-Si EPIDs incorporated on the two LINACs – the Edge™ LINAC has 
probably a better EPID than the TrueBeam™ LINAC. Regarding the introduction of errors (MUs, MLC 
position - random and systematic -, and collimator angle) in the XML files with the patient plans, for a 3 
%/3 mm gamma analysis, we have concluded that EPID is sensitive to the different types of error introduced. 
When comparing EPID sensitivity with ArcCHECK sensitivity, the results obtained suggested that EPID is 
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as sensitive as ArcCHECK and, on top of that, shows more coherent results. Finally, when verifying the 
influence of the introduced errors in the organs at risk (OARs), we have obtained, as expected, that, higher 
the magnitude error introduced, higher the volume difference values, consequently, lower the gamma 
passing rate values, and higher effects in the organs at risk.  
In the end, the analysis of the results showed that EPID, at the same time, allows better results, and 
is more sensitivity, than ArcCHECK. However, more clinical cases, considering several treatment sites and 
with diﬀerent fractionation schemes, should be studied with both portal dosimetry and ArcCHECK to verify 
the obtained results. Due to the very promising results obtained, for the first time at Champalimaud 
Foundation, EPID had started to be routinely used in pre-treatment patient-specific QA on Edge™ LINAC. 
Therefore, this only encourages the continuation of the study for implementation of pre-treatment patient-
speciﬁc QA with EPID on the Varian TrueBeam™ LINAC, as well as the implementation of in vivo patient-
specific QA. 
Key- words: Tumor; Quality Assurance; Pre-Treatment Dosimetry; EPID Dosimetry; Gamma 
Analysis. 
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CHAPTER 1. INTRODUCTION 
1.1 Motivation 
 
At the Radiotherapy Department of Champalimaud Foundation, we currently have two different 
treatment systems (Elekta and Varian), each one of them with their own portal dosimetry software (PDAPP 
and Portal Dosimetry, respectively). Besides these two software, a software called PreDose, that does pre-
treatment and in vivo dosimetry at the EPID level for the Elekta machines, has been developed, and a new 
in vivo dosimetry software from MAASTRO (Netherlands), for the Varian machines, has just arrived to be 
tested. 
 
Despite the existence of these four software, none of them is being routinely used in the clinic due 
to the absence of their full implementation. At the moment, individual patient plan QA is performed pre-
treatment by the more cumbersome and low-resolution ArcCHECK (SunNuclear®), which uses diode 
arrays for performing measurements. 
 
In the case of this project, I will focus my attention on the Varian system, leaving the Elekta system 
aside. The main goals of the present project are to finalize measurements and comparisons and test new 
software versions, compare EPID dosimetry data with ArcCHECK data for many patients, and determine 
the sensitivity of one of the Varian systems by purposely introducing errors in a set of test plans. When 
satisfactory results are obtained, clinical procedures and criteria for Varian systems will be developed, and 
pre-treatment dosimetry with EPID (Portal Dosimetry) is going to replace ArcCHECK measurements, in 
order to improve the accuracy of QA measurements and the efficiency at the Radiotherapy Department of 
Champalimaud Foundation.  
 
Thus, this project which aims to replace ArcCHECK QA measurements and bring into the clinic 
the routine use of EPID to perform QA measurements, is of utmost importance once it will greatly facilitate 
and improve the operation of the clinic. 
1.2 Contextualization 
 
Cancer is one of the major public health problems in Europe, in the United States, and other 
countries in the western world [1]. 
 
Radiotherapy is one of the main treatment methods for cancer along with surgery, chemotherapy, 
and hormone therapy, once it (alone or in combination with other treatments) is a curative treatment for 40 
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% of the cancer patients receiving it. Among the most commonly used radiotherapy methods are 3D 
conformal radiation therapy (3D CRT), intensity modulated radiotherapy (IMRT), and particle beam therapy 
[1]. 
 
Intensity modulated radiotherapy (IMRT) is an advanced mode of high-precision radiotherapy 
which offers a dose distribution improvement by modulating the two-dimensional X-ray fluence. It uses 
computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific 
areas within the tumor [2][3].  
  
With the increased use of intensity modulated radiotherapy and, consequently, increasing in 
treatment plans complexity, and higher dose prescriptions, the demand for patient specific verification has 
increased. Besides that, the possibility of deviations from the plan dose during the treatment planning 
process and data transfer problems, make it more difficult to discover possible errors. Due to this increasing 
need for patient specific verification, recommended QA procedures might no longer be sufficient and, 
therefore, new procedures are necessary to detect possible errors. Films and EPIDs are generally used for 
this purpose [3]. 
 
Electronic portal imaging devices (EPIDs) provide an advanced tool with digital technology to 
improve target localization and maintain clinical efficiency. Therefore, they can eventually be used for 
intensity modulated radiation therapy (IMRT) QA. In fact, not long after their clinical introduction for set-
up verification, it was realised that EPID images contain dose information. Consequently, several groups 
started to investigate the dosimetric characteristics of various types of EPID. Nowadays, in some places, 
EPIDs have gone on to replace traditional dosimetry devices in the clinic for plan verification. EPID 
dosimetry has a lot of advantages such as fast image acquisition, high resolution, digital format, and potential 
for in vivo measurements and 3D dose verification, which make it a very promising tool [2][4][5]. 
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CHAPTER 2. BACKGROUND 
2.1 External Beam Radiotherapy 
 
Radiotherapy is one of the most widely used cancer treatment method. The goal of radiotherapy is 
to irradiate tumor tissue with a high dose while sparing the surrounding normal healthy tissue as much as 
possible to limit the complications of a patient treatment. 
 
Depending on the location of the radiation source, internal and external beam radiotherapy can be 
distinguished. Once internal beam radiotherapy uses radioactive sources placed on the surface or inside of 
the patient in a very close location of the tumor, external beam radiotherapy uses ionising radiation sources 
placed at a distance from the patient. In general, nowadays, irradiation is done by using external beam 
radiotherapy or brachytherapy [1].  
 
Brachytherapy is an advanced cancer treatment where radioactive seeds or sources are placed in or 
near the tumor itself, giving a high radiation dose to the tumor while reducing the radiation exposure in the 
surrounding healthy tissues. The term "brachy" is Greek and means “short distance” [6]. 
 
In case of external beam radiotherapy, a radiation beam is pointed at a particular part of the body. 
By using multiple beams in an optimum beam angle configuration, the dose in healthy tissue can be 
diminished. Different types of radiation have different interactions with tissue, and will cause more or less 
biological damage. The most commonly ionising radiation types used in external beam radiotherapy are 
megavoltage X-rays (megavolt or MV photon beams), electrons and protons, produced by a LINAC (linear 
accelerator). 
 
At the Radiotherapy Department of Champalimaud Foundation, the external beam radiotherapy is 
accomplished by using megavoltage X-rays, MV photon beams in particular. Clinical megavoltage X-rays 
beams typically have an energy range between 10 kVp and 50 MV, and are the result of the deceleration of 
electrons with kinetic energies between 10 keV and 50 MeV in special metallic targets. A major part of 
electron’s kinetic energy is converted in the target into heat, while a small fraction of the energy is emitted 
in the form of X-ray photons [7]. 
 
External beam radiotherapy is based on interactions of ionizing radiation with matter, and its goal 
is to eliminate the reproductive capacity of the cells. Thus, to fully understand the effectiveness of external 
beam radiotherapy in cancer treatment, it is essential to understand the inherent radiobiological principles. 
2.1.1 Radiobiological Principles 
In order to control tumor volume while preserving the integrity of the healthy tissues, fractionated 
radiotherapy schemes have been widely prescribed. Conventional fractionation schemes comprise 
administering 1.2 to 2.0 Gray (Gy) per fraction, 5 days per week, giving a total dose between 60 and 70 Gy 
which varies according to the tumor volume and the maximum dose that the adjacent healthy tissues tolerate. 
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The effect of radiation administrated in fractionated schemes is governed by ﬁve radiobiological principles, 
known as the 5R’s: (1) Repair of sublethal damage, (2) Repopulation of cells after radiation, (3) 
Redistribution of cells in the cell cycle, (4) Reoxygenation of the surviving cells and (5) Radiosensitivity of 
tumor cells [8][10][11]. 
 
The ﬁrst radiobiological effect (repair of sublethal damage), describes the capacity of the cells in 
repairing sublethal damage induced by radiation, returning to the initial sensitivity values. While health cells 
exhibit a high capacity to repair sublethal damage, tumor cells exhibit a low capacity to repair sublethal 
damage, leading to the accumulation of irreversible damage, and causing cell death. It is important to note 
that the rate of the repair damage induced by radiation is directly related to several factors including the 
dose per fraction, and the nature of the tissues and cells [8][10].  
 
The second radiobiological effect (repopulation of cells after radiation) is the process by which 
healthy cells irreversibly damaged or killed are replaced by cell proliferation after a fraction [8]. 
 
The third radiobiological effect (redistribution of cells in the cell cycle), refers to the process in 
which cells progress through the cell cycle reaching the most sensitive stage of radiation. As known, the 
sensitivity of the cells varies according to the stage of the cell cycle. For example, in mitosis, cells are more 
sensitive to radiation since the DNA compaction makes it more susceptible to the damaging effects of 
radiation as well as less accessible to the repair enzymes. Tumor cells have a high mitotic rate (greater 
proliferative capacity) and, therefore, are considered more radiosensitive than healthy tissues. As a result, 
fraction to fraction, there is a higher proportion of the surviving tumor cells in the mitosis stage [8]. 
 
The fourth radiobiological effect (reoxygenation of the surviving cells) corresponds to the process 
by which the hypoxic cells become oxygenated after irradiation. The more oxygenated areas of the tumors 
are located at the periphery, while the less oxygenated areas are in central regions. Therefore, once as more 
oxygenated tumors, more radiosensitive they are considered, after a fraction, cells at the periphery will die 
more quickly, being the oxygen redirected to neighboring cells with low oxygen content. This results in an 
increase of oxygenated tumor cells in the next fraction - reoxygenation of the surviving cells [8]. 
 
Finally, the last radiobiological effect (radiosensitivity of tumor cells) is considered an intrinsic 
factor and it is modelled by the linear-quadratic (LQ) equation. The LQ is used to calculate the effects for 
different fractionated irradiation schemes comprising dose and fraction number [9][10].  
 
In recent years, a signiﬁcant interest in hypofractionated schemes, higher than 2.5 Gy per fraction, 
has been observed mainly inﬂuenced by the clinical results obtained by stereotactic radiosurgery (SRS). 
Some studies conducted with high-dose fractionated schemes concluded that the capacity of healthy cells to 
repair sublethal damage is signiﬁcant during the treatment session, which is more prolonged in 
hypofractionated or single shot schemes than in conventional schemes, enabling to healthy cells to return to 
the initial sensitivity values. Tumor irradiation in a single fraction prevents cell cycle redistribution and 
tumor cells death in the cell cycle phases where they are irradiated. The repopulation of tumor cells during 
treatment is also negligible since the treatment is completed within 1 or 2 weeks. For tumors treated with a 
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single fraction or extremely high-dose fraction, vascular damage is so extensive that the intra-tumor 
environment is drastically changed leading to indirect cell death. Consequently, the LQ model is 
inapplicable when tumors are treated with doses higher than 10 Gy in a single fraction, being only 
considered when tumors are treated with hypofractionated schemes with doses smaller than 10 Gy per 
fraction [9][10][11]. 
2.1.2 LINAC (Linear Accelerator) 
A linear accelerator (LINAC) customizes the radiation field (high energy X-rays) according to the 
tumor’s shape, and destroys cancer cells, while sparing surrounding normal tissue. It is the most common 
device used to treat cancer with external beam radiation. Despite its own several built-in safety measures 
that ensure that a higher dose than the prescribed one will not be delivered, it must be routinely checked to 
ensure that it is working properly [12][13]. 
 
Medical LINACs are cyclic accelerators that use radiofrequency (RF) waves to accelerate charged 
particles (electrons) to high energies. In this, the electrons collide with a heavy metal target to produce 
energy X-rays [14]. 
 
In the case of the LINACs at the Radiotherapy Department of Champalimaud Foundation, the 
charged particles used are electrons. The electrons are accelerated in a linear path inside special evacuated 
structures called accelerating waveguides and, to produce the high-power RF fields needed for electron 
acceleration, special evacuated devices called magnetrons and klystrons are used. Basically, the accelerated 
electrons collide with a primary target, being decelerated, and emitting braking radiation (bremsstrahlung), 
which will result in the production of X-rays. The X-rays produced are then customized either by blocks 
positioned in the head of the LINAC or by a multi-leaf collimator incorporated in the head of the LINAC 
[7][13]. A scheme of this process is shown in the figure below, Figure 2.1. 
 
 
Figure 2.1. Production of high energy X-rays by the LINAC. Retrieved from [15]. 
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As said before, the LINACs available at the Radiotherapy Department are three - Edge™ and 
TrueBeam™ LINAC, from Varian, and Synergy™ LINAC, from Elekta. The TrueBeam™ LINAC is an 
advanced image-guided radiation therapy (IGRT) system used to treat cancer with speed and accuracy while 
avoiding healthy tissues and organs. TrueBeam™ was designed for complex cases of cancer of the lung, 
breast, stomach, and brain. It can also be used for cases of cancers of the liver and prostate, along with other 
cancers treated with radiation therapy. The Edge™ LINAC was the latest addition and it is a state-of-the-
art linear accelerator coupled with real-time motion management to ensure fast and precise delivery of 
treatment. It has the highest dose rate in the industry allowing for faster treatments. The quality and safety 
system of the Edge™ performs accuracy checks every 10 milliseconds to ensure quality of care. Finally, the 
Synergy™ LINAC was the first linear accelerator to bring 3D image guidance into the treatment set up 
process and was the first being acquired at the Radiotherapy Department of Champalimaud Foundation. The 
main difference between these three LINAC is the characteristics of the multi-leaf collimator (MLC) 
incorporated in the LINAC that make them more appropriate for some cases than for the others. 
 
One important aspect to be referred is that the LINAC output is measured in terms of some special 
units called monitor unit (MU), using two ionisation chambers. Thus, the ﬁrst ionisation chamber measures 
the MU and stops the beam when the pretended radiation it is completely delivered, while the second 
ionisation chamber provides a backup in case of failure of the ﬁrst chamber. 
 
MU (Monitor Unit) 
As mentioned before, monitor unit (MU) is a measure of a machine output such as a LINAC. The 
most common definition, and the one used in this thesis, is that the ionisation chamber reads 1 MU when an 
absorbed dose of 1 cGy is delivered to a point at a given depth in the phantom, with the surface of the 
phantom positioned so that the specified point is at the isocentre of the machine and the field size is 10 cm 
× 10 cm at the isocentre. This is an important measurement, as the output of the linear accelerator can only 
be read in charge passing through the ionisation chamber. 
 
2.1.3 MLC (Multi-Leaf Collimator) 
Multi-leaf collimators (MLCs) are an addition to LINAC dose delivery technology. They are beam 
shaping devices used as a replacement for collimator blocks and, without them, the LINAC would only be 
capable of treating quadrangular or rectangular treatment fields. Each leaf in the MLC has, typically, a width 
at the isocenter ranging from 0.5 cm to 1 cm, and can be individually moved to match each treatment plan 
and enhance dose delivery. A MLC incorporate from 20 to 60 pairs of narrow closely abutting tungsten 
leaves. [7] 
 
The MLCs may be an integral part of the LINAC head, replacing upper or lower secondary 
collimator jaws, or may be attached to the LINAC’s head and used in conjunction with both the upper and 
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lower collimator jaws. In the figure below, Figure 2.2, there is a typical MLC attached to a LINAC head 
and used in conjunction with the upper and lower collimator jaws. 
 
 
Figure 2.2. MLC with 60 pairs of abutting tungsten leaves (TrueBeam™ MLC, Varian). Adapted from [16]. 
 
On the one hand, the advantages of an MLC include simple and less time-consuming preparation, 
ability to treat multiple fields without re-entering the treatment room, simple change or correction of field 
shape, lower therapy expenses once individual shielding block are not need and, therefore, there is no need 
to handle the toxic wood’s alloy, shorter therapy time, and continuous adjusting of field shape during 
irradiation in advanced conformal radiotherapy. On the other hand, the disadvantages of an MLC include 
the discrete step size of the leaves resulting in stepping edge effect, additional quality assurance 
requirements, additional data to characterize the output factors, wider penumbra (the penumbra is the region 
at the edges of the radiation beam where the dose rapidly decreases), radiation leakage through and between 
leaves, and, eventually, problems with generating some complex field shapes [7]. 
2.1.4 IMRT (Intensity Modulated Radiotherapy) 
IMRT is currently one of the most advanced form of conformal radiotherapy, and is being used 
most extensively to treat cancers of the prostate, head and neck, and central nervous system. It is also being 
used to treat cancers of the breast, thyroid, and lung, as well as gastrointestinal and gynecologic 
malignancies, and certain types of sarcoma [7][17]. 
 
This technique uses computer-controlled linear accelerators to deliver precise radiation doses to a 
malignant tumor or specific areas within the tumor, and allows for the radiation dose to conform more 
precisely to the three-dimensional shape of the tumor. Thus, beams of radiation are guided to the tumor 
from many different angles and, at each of these angles, the intensity of the radiation is modulated, and the 
shape of the beam is changed to match the shape of the tumor [7][18]. 
 
In comparison with conventional techniques, IMRT allows higher and more effective radiation 
doses to be safely delivered to tumors, with fewer side effects. Besides that, IMRT has the potential to 
  
27 
reduce treatment toxicity, even when doses are not increased. However, due to its complexity, IMRT does 
require slightly longer daily treatment times, additional planning, and safety checks before the patient can 
start the treatment [7][17][18]. 
 
Various approaches to IMRT have been developed. MLC based IMRT techniques are the most 
currently used and can be divided in two categories: one uses multiple static MLC shaped fields, and the 
other uses dynamic MLC dose delivery approaches. In IMRT treatments, the MLC can be operating in one 
of three basic modes: the segmented MLC (SMLC) mode (static IMRT), often referred to as step and shoot 
mode, where there is no MLC motion while the beam is on; the dynamic MLC (DMLC) mode (dynamic 
IMRT), sometimes referred to as the sliding window mode, where the intensity modulated fields are 
delivered in a dynamic mode with the leaves of the MLC moving during the irradiation of the patient; and 
the intensity modulated arc therapy (IMAT), where the sliding window approach is used as the gantry rotates 
around a patient [7]. 
 
Nowadays, a novel radiation technique called volumetric modulated arc therapy (VMAT) is being 
increasingly used by the clinical worldwide. VMAT is an advanced form of IMRT that delivers a precisely-
sculpted 3D dose distribution with a 360-degree rotation of the gantry in a single or multi-arc treatment. 
Thus, this technique differs from existing techniques, such as IMAT, once it delivers to the whole volume, 
rather than slice by slice [19]. 
 
Unlike conventional IMRT treatments, during which the machine must rotate several times around 
the patient, or make repeated stops and starts to treat the tumor from many different angles, VMAT can 
deliver the dose to the entire tumor in a 360-degree rotation, typically in less than two minutes. Thus, the 
advantages of VMAT include highly conformal dose distributions with improved target volume coverage, 
while sparing normal tissues, as well as reduced treatment delivery time [19][20]. 
2.1.5 FFF Beams 
The improvement of IMRT and VMAT, as well as the development of new radiotherapy schemes 
where large MUs are often required, have increased the interest in operating the LINAC in a ﬂattening ﬁlter 
free (FFF) mode. 
 
The main beneﬁt of FFF beams relies on the possibility of deliver higher dose rates, requiring a 
shorter delivery time. Less delivery time means that the patient is on the treatment couch for a shorter period, 
which will improve patient comfort and decrease the possibility of inaccuracies due patient movement.  
 
2.2 Clinical Procedure in Radiotherapy 
2.2.1 Radiotherapy Chain 
In radiotherapy, each clinical process is complex and involves several steps as illustrated in Figure 
2.3. 
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Figure 2.3. Radiotherapy chain for each clinical process. 
First, the radiation oncologist evaluates the disease stage, and decides between a curative and a 
palliative treatment. Depending on the characteristics of the tumor, the treatment, or combination of 
treatments, is decided (radiotherapy, chemotherapy, etc.). If the treatment chosen is radiotherapy, the 
process starts with imaging the patient’s anatomy at the tumor site using computed tomography (CT), and 
sometimes magnetic resonance imaging (MRI), to enhance the soft tissue contrast. Then, the radiation 
oncologist delineates the target volume as organs at risk (OARs) from the acquired CT, and defines the dose 
to be prescribed with the support of a treatment planning system (TPS). After the delineation, the next step 
is to calculate the dose and optimize the dose distribution obtained. This is done by dosimetrists using a 
TPS. The dose distribution is then evaluated by a physicist that verifies the dose restrictions to the healthy 
tissue and to the target volume. One way of doing this is to use dose-volume histograms (DVHs) which are 
a valuable tool that summarize the information contained in the 3D dose distributions and, consequently, 
can be used to verify if the prescribed dose correctly covers the target volume, and if the irradiation of the 
OARs doesn’t exceed the international recommendations. Finally, the radiation oncologist decides if the 
plan meets all the aims and restrictions defined, or if a new plan is needed. If the plan is approved, the 
treatment can start. Before the treatment, a pre- treatment QA is done with the support of a phantom or EPID 
and, only if the QA gamma passing rate obtained is high enough (higher than a certain established limit 
value, usually 90 %), the patient is treated. Note that in cases that the QA gamma passing rate is under the 
established limit value, a new plan has to be done, and the patient is said to be replanned. Preferably, during 
the treatment, in vivo QA is performed using EPID to check the dose actually received by the patient. 
Delineation 
In the delineation step, the radiation oncologist contours, generally manually and slice-by-slice, the 
organs at risk (OARs), and the target volumes. OARs are critical normal tissue structures which might be 
signiﬁcantly damaged by the radiation depending on the tumor site (for example, for prostate patients, the 
OARs would be the bladder, the rectum, and the right and left femur head). The target volumes include: the 
gross tumor volume (GTV), the clinical target volume (CTV), the internal target volume (ITV), and the 
planning target volume (PTV) (see Figure 2.4). The GTV is based on the information obtained from the 
combination of image, diagnose, and clinic examination modalities. The CTV often includes the area that 
surrounds directly the GTV, and can contain microscopic diseases and other areas considered to be at risk 
and needing treatment. The ITV consists in the CTV plus an internal margin drawn to take in account 
variations in the size and position of the CTV regarding the patient’s referential, as well as the internal 
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movements. Finally, the PTV includes the internal target margin and an additional margin to uncertainties 
in the configuration, machine tolerations, and intra-treatment variations. 
 
 
Figure 2.4. Graphical representation of the volumes of interest: the gross tumor volume (GTV), the clinical target volume 
(CTV), the internal target volume (ITV), and the planning target volume (PTV). Retrieved from [7]. 
In the figure below, Figure 2.5, we can see an example of a CT of a patient with a tumor in the right 
breast, and the contouring of the target volumes and OARs. 
 
 
Figure 2.5.  CT of a left breast cancer patient with the OAR (heart), the PTV, and the CTV contoured. Retrieved from [26]. 
Planning 
After the delineation, the dosimetrist has to calculate the dose and optimize the dose distribution 
obtained. For that, it uses a treatment planning system (TPS) that determines the beam geometry to obtain 
the desired dose to the target volumes, while sparing the organs at risk. An example of this procedure is 
shown in Figure 2.6 where the two fields irradiating the PTV and the dose distribution are calculated by the 
TPS. 
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Figure 2.6. Determination of the beam geometry by the TPS. Retrieved from [27]. 
 
The dose distribution is then evaluated by a physicist that verifies the dose restrictions to the healthy 
tissue and to the target volume using a TPS. 
Treatment Planning System 
At the Radiotherapy Department of Champalimaud Foundation, Eclipse™ is the TPS used for the 
Varian machines, while Monaco™ is the TPS used for the Elekta machine. 
  
Eclipse™ is a software from Varian that provides an interface for treatment planning including 
contouring of the structures, beam planning, dose calculation, and plan evaluation. Its calculations rely on 
the beam data describing the output of the machine and several algorithms can be used to calculate the dose 
[25]. 
 
Monaco™ is a software from Elekta that delivers high performance and high precision radiotherapy 
treatment planning for photon and electron based plans. It combines Monte Carlo and collapsed cone 
algorithms, handling very complex plans with high accuracy [30]. 
Pre-Treatment vs In Vivo Patient-Specific QA 
In the case of the Radiotherapy Department of Champalimaud Foundation, the pre-treatment 
patient-specific QA is still performed routinely with the support of ArcCHECK in the three LINAC 
available (TrueBeam™ and Edge™, Varian, and Synergy™, Elekta), and the in vivo QA is only performed 
sporadically in one of the LINAC available (Synergy™, Elekta). That is the reason why this project is so 
important, and the implementation of portal dosimetry in all the available LINAC is so needed. 
 
2.2.2 Quality Assurance 
The use of IMRT and VMAT in clinical routine is spreading rapidly, and the possibility of treating, 
simultaneously, different target volumes, with different fractionations, is opening new possibilities. 
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However, a practical drawback on the implementation of IMRT into the clinical routine remains the time-
consuming patient specific quality assurance (QA) that precedes the actual treatment [21][22]. 
 
Patient specific quality assurance (QA) is an essential step to guarantee accurate patient treatment 
in radiotherapy, and is performed at various levels starting with the QA of machine- related parameters such 
as beam flatness and stability, accuracy of the leaf positions of a multi- leaf collimator (MLC), and accurate 
modelling of the LINAC at the commissioning stage of the treatment planning system (TPS). 
 
When administering radiotherapy in a fractionated manner (i.e., giving every day a small dose of 
radiation), a small difference in biological radiation sensitivity between tumor and healthy tissue can be 
exploited to increase the overall tumor dose, increasing tumor control probability with acceptable normal 
tissue complication probability. Consequently, every fraction must be given in a reproducible way, and the 
dose delivery in a patient should be as close as possible to the prescribed dose calculated with the TPS. To 
achieve a high accuracy in absorbed dose delivery, it is of utmost importance that the dose delivery is 
verified during external MV photon beam treatment [23]. 
 
Dose verification can be accomplished in many ways. The most widely used form of pre- treatment 
QA for IMRT generally consists of dose measurements (with film, ionization chamber, diode, TLD, etc.) 
combined with isodose measurements in a phantom, or even by means of gel dosimetry. Radiographic and 
radiochromic films can be used to verify dose distributions in two dimensions and have a high spatial 
resolution (i.e., higher ability to differentiate two objects). Once in IMRT treatments we have the presence 
of high dose gradients in the plane of the beam, films have been especially used for the verification of these 
types of treatments. However, films have some disadvantages that include the time-consuming dose 
evaluation and the possibility of errors during processing, digitizing and analysing. Other dosimetry system 
currently available to perform dose verification is gel dosimetry. Gel dosimetry allows a measurement of 
the 3D dose distribution but is limited by the complex preparation process and the expensive analysis using 
a magnetic resonance (MRI) scanner. Finally, a more efficient tool for pre-treatment patient-specific QA is 
the electronic portal imaging device (EPID). These types of dosimetry device are already attached to the 
LINAC, providing real-time digital feedback to the user, with no need of additional hardware to perform 
portal dosimetry. EPID measurements can be performed with minimum set-up requirements, and a 2D dose 
conversion can be done immediately using the digital images. Although an EPID image contains 2D and 
not 3D information, it is still possible to reconstruct the 3D dose distribution inside a patient by using a 
back-projection procedure of the measured portal dose image (PDI) into three dimensions. For a typical pre-
treatment patient-specific QA scenario by means of a portal imager, two requirements must be met: firstly, 
a proper acquisition mode must be available to detect all dose deposited in the imager during irradiation of 
the treatment field; secondly, one needs to be able to predict what the integrated portal dose image should 
look like for correct delivery of the fluence distribution [23][24]. 
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ArcCHECK 
At Champalimaud Foundation the pre-treatment patient-speciﬁc QA is performed using a 
cylindrical detector array called ArcCHECK (©SunNuclear), which uses 2D matrix of diodes arrays for 
performing measurements. ArcCHECK displays beams eye view (BEV) dose distribution throughout the 
entire arc delivery, and the diode arrays are always facing the delivery beam regardless of gantry angle, i.e., 
the detector geometry relative to the BEV remains constant. 
 
Besides its recurrent use, ArcCHECK it is not the best option once it has a low resolution, and makes 
the pre-treatment patient specific QA a time-consuming and cumbersome procedure. In this line of thought, 
it becomes essential to optimize the pre-treatment patient-speciﬁc QA procedure currently performed at 
Champalimaud Foundation to detect more accurately possible errors and to decrease the time dispensed by 
the physics. This assumes even more importance if we take in consideration that 24 % and 35 % of total 
treatments conducted in both Varian LINAC have hypofractionated and single shot schemes, respectively.  
2.3 EPD (Electronic Portal Dosimetry) 
 
Electronic portal image devices (EPIDs) were originally designed and developed for visual 
inspection of patient set-up during radiotherapy sessions. However, for over a decade, the electronic portal 
imaging device (EPID) has undergone extensive development and use as a dosimeter for intensity modulated 
radiotherapy (IMRT) patient specific quality assurance (QA). Patient specific quality assurance includes 
both pre-treatment verification and in vivo dosimetry [24][31]. 
2.3.1 EPID (Electronic Portal Imaging Device) 
The published literature suggests that the development and use of electronic portal image devices 
(EPIDs) began in the 1950s. EPIDs can be distinguished mainly according with two categories: optical 
systems and non-optical systems. 
 
Regarding the optical systems, one pioneering system developed was a camera based EPID that 
comprised an X-ray image intensifier tube whose light output was optically coupled via a mirror-lens 
arrangement to a Vidicon TV camera (Strandqvist et al 1958, Wallman et al 1958). A similar system 
developed consisted of a fluorescent screen coupled to an Orthicon camera via a mirror-lens combination 
(Andrews et al 1958). This system was modified by adding a metal plate in front of the fluorescent screen 
(Benner et al 1962), and developed and refined years later by several groups (Leong 1986, Shalev et al 1989, 
Munro et al 1987, 1988, 1990a, 1990b, Ezz et al 1991, Swindell et al 1991, Racliffe et al 1993, Jaffray et al 
1995a, 1995b, Bissonnette et al 1994, 1997a, 1997b, Drake et al 2000). The commercialization of camera 
based EPIDs started in the late 1980s. An alternative two-dimensional optical technology for electronic 
portal imaging based on thin film electronics of the sort used in active matrix liquid crystal displays was 
developed (Antonuk et al 1991a, 1992a, 1998a, 1998b). This system so called amorphous-silicon EPID (a- 
SI EPID) or flat-panel imager, consisted of a phosphorus screen and a thin-film transistor diode array. In 
addition to these two-dimensional optical systems, another interesting optical system approach involved a 
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one-dimensional detector array scanned across the field of view (Morton and Swindell 1987, Morton 1988, 
Morton et al 1991) that offered high quality images. A new version of this type of EPID that allows increased 
light yield, and a better signal-to-noise ratio, was developed years later (Spies et al 2000, Evans et al 2000) 
[3][25]. 
 
While the bulk of efforts to develop optical EPIDs have been directed toward two-dimensional 
systems, this was not the case for non-optical systems. The first non-optical system developed consisted of 
a scanning linear array of silicon diodes (Taborsky et al 1982, Lam et al 1986, 1987) and photovoltaic diodes 
(Entine et al 1992, 1993). While the first device was known as a scanning liquid-filled ionization chamber, 
the second device was known as a scintillation crystal-photodiode. Another non-optical system developed 
was based on a two-dimensional matrix ionization chamber (Van Herk and Meertens 1987, Van Herk 1991, 
Van Herk et al 1992, Merteens et al 1985, 1990). This system was commercially available since 1990 and, 
like the camera-based EPID systems using a metal plate/phosphor screen, produced images with significant 
amounts of clinically useful information. More recently, two other novel non-optical approaches for EPID 
design have been explored: a one-dimensional scanning system employing the kinestatic charge detection 
principle (DiBianca et al 1997, Samant et al 1999), and a dual-energy two-dimensional imager consisting 
of multiple gas-electron multiplier detectors (Brahme et al 2000, Ostling et al 2000, Iacobaeus et al 2001) 
[3][25]. 
  
Basically, EPIDs can be of four different types: scanning liquid-filled ionization chamber, 
scintillation crystal-photodiode, camera-based EPID, and amorphous-silicon EPID (a-SI EPID) or flat-panel 
imager. 
 
The type of EPID most widely used and available today is the amorphous-silicon EPID (a-Si EPID) 
or flat-panel imager (Antonuk et al 1995, 1998). The panel consists in an X-ray converter that is optically 
coupled to a camera by means of a mirror and a lens, a light detector, and an electronic acquisition system 
for receiving and processing the resulting digital image. The converter consists in a flat metal plane, which 
serves to convert incident primary X-rays into high energy electrons, as well as to block low energy scattered 
radiation, and a gadolinium oxysulfide phosphor screen which serves to convert primary X-rays into high 
energy electrons, and transforms a fraction of the energy of the high energy electrons passing through it into 
light. Some of the light diffuses through the screen, exiting on the mirror side. Then, a fraction of this 
emerging light is captured by the camera and lens and transformed into a video signal that is sent to other 
hardware for digitization, processing, display and archiving. The reason a-Si detectors have become 
increasingly popular for portal imaging is because they have relatively higher detector quantum efficiency 
than, for example, the liquid filled ionization chamber EPID, requiring less patient dose for the same portal 
image [3][21]. 
 
Basically, EPID is a heavy piece of hardware mounted on a support arm that allows vertical, lateral, 
and longitudinal translations, as well as a pitch rotation. 
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2.3.2 PDI (Portal Dose Image) 
A portal dose image (PDI) is acquired with the radiation obtained from the radiotherapy treatment, 
and it consists in a 2D distribution of the photon transmission behind a patient during the external beam 
radiotherapy. Initially, portal images were obtained using films, and used to verify the patient position once 
they show the irradiated area. However, as the time passed by, films were replaced by EPIDs, once EPIDs 
allow the acquisition of digital images with high precision. Nowadays, the use of portal images has been 
extended to treatment verification. 
2.3.3 Dosimetric Calibration of an a-Si EPID 
The standard calibration of EPID requires the acquisition of a dark-ﬁeld image, a ﬂood-ﬁeld image 
and a defective pixel map to achieve a more uniform EPID response. The dark-ﬁeld image is the average of 
several frames acquired without radiation and, therefore, it is the same for all treatment energies. The flood-
field image is the average of several frames acquired by irradiating EPID with an open uniform ﬁeld, large 
enough to cover the entire active matrix. The defective pixel map identiﬁes all the nonresponding pixels to 
assign them the mean value of the neighboring pixels [21]. 
 
First, to correct individual pixel background signals, the dark-ﬁeld image is obtained (the same for 
all treatment energies). Then, for each treatment energy, a flood-field image is acquired to normalize each 
individual pixel response, correcting differences in pixel sensitivities. Finally, to enhance the image quality, 
a defective pixel map is acquired. It is important to note that, before to be stored and displayed, each frame 
acquired by EPID is automatically darkﬁeld and ﬂood-ﬁeld corrected by the image acquisition system. 
Therefore, each portal image (PIRaw) is subtracted by the dark-ﬁeld (DF) image and divided by the 
normalized ﬂood-ﬁeld (FF) image, which is also dark-ﬁeld corrected, and multiplied by a mean value of the 
normalized ﬂood-ﬁeld image (FFMean) according with the next equation, 
 
𝑷𝑰𝒄𝒐𝒓𝒓𝒆𝒄𝒕𝒆𝒅(𝒙, 𝒚) =
𝑷𝑰(𝒙,𝒚)−𝑫𝑭(𝒙,𝒚)
𝑭𝑭(𝒙,𝒚)
× 𝑭𝑭𝒎𝒆𝒂𝒏 (Equation 2.1) 
 
Ideally, for dosimetry purposes the FF image should be perfectly ﬂat. However, since the FF image 
is generated from an open photon beam, it exhibits the characteristics horns caused by the ﬂattening ﬁlter. 
Therefore, the FF image not only corrects pixel-to-pixel sensitivity variation or off-axis differential energy 
response, but also removes the beam proﬁle present in the acquired portal image causing spatial distortions 
in the ﬂuence distribution. For this reason, a previously calculated or measured (with ﬁlm or ionization 
chamber in water) beam proﬁle (BP) is used to restore the initial beam proﬁle of the acquired portal image, 
so 
 
𝑃𝐼𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑(𝑥, 𝑦) =
𝑃𝐼(𝑥,𝑦)−𝐷𝐹(𝑥,𝑦)
𝐹𝐹(𝑥,𝑦)
× 𝐹𝐹𝑚𝑒𝑎𝑛 × 𝐵𝑃 (Equation 2.2) 
 
To perform dosimetric calibration of EPID, two different approaches have been adopted: prediction 
of the grayscale pixel value or conversion of grayscale pixel value to dose or ﬂuence value. The ﬁrst one 
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models the EPID response by Monte Carlo simulation or empirical models and, for this reason, an accurate 
and detailed knowledge regarding EPID composition is required. In turn, the second approach converts the 
portal image acquired by EPID into a portal dose image applying empirical models based on measurements 
in water with a calibrated detector, usually an ionisation chamber. In general, converting grayscale values 
to dose or ﬂuence is simpler and faster than a modulation of the EPID response and, therefore, more suited 
for clinical implementation. 
2.3.4 Methods of EPID Dosimetry 
There is no clear consensus in the literature on the definition of various procedures and methods 
related to EPID dosimetry. However, below, there is a definition of various terms as used in this thesis. 
 
Verification procedures can be classified according to whether they are performed during treatment 
time (i.e. with the patient), or outside of treatment time (i.e. without the patient). Thus, we can have: 
• Pre-treatment verification (without the patient), where the whole or part of the intended treatment 
plan is compared with measurements of corresponding radiation beams delivered by the linear 
accelerator outside patient treatment time, i.e., with open fields (without anything) or a phantom; 
• Treatment verification (with the patient), where all or part of the planned dose is compared with the 
delivered dose distribution based on measurements acquired during patient treatment time [3]. 
 
Dosimetry methods, independent of the type of detector used, can be grouped according to whether 
beams have passed through an attenuating medium, or whether the dose is reconstructed inside a phantom 
or patient. We can have: 
• Non-transmission (or non-transit) dosimetry (without an attenuating medium), which consists in the 
determination of the dose in the detector, patient or phantom, or determination of the incident energy 
fluence, based on measurements without an attenuating medium between the source and the 
detector, i.e., phantom or patient; 
• Transmission (or transit) dosimetry (with an attenuating medium), which is based in the 
determination of the dose at the position of the detector, patient or phantom, or determination of the 
incident energy fluence, based on radiation transmitted through the patient or phantom; 
• In-phantom dosimetry (inside a phantom), which consists in the measurement or determination of 
the dose inside a phantom (rarely performed with EPIDs but included for completeness). This can 
be the dose at points, lines, planes, or volumes within the phantom; 
• In vivo dosimetry (inside a patient), that relies on measurement or determination of the dose inside 
the patient. Measurements performed during treatment can be performed invasively, i.e., inside the 
patient, or non-invasively, i.e., at some distance from the patient, whereby the in vivo dose at the 
point of interest is obtained by extrapolation [3]. 
2.3.5 Pre-treatment Verification vs In Vivo Dosimetry 
Portal dose images are frequently used for pre-treatment verification of IMRT fields, and in vivo 
dosimetry. As said before, in the first case, the goal is to verify the accuracy of dose delivery in a phantom 
prior to the first radiotherapy session and, therefore, to detect errors before the first fraction. For that, an 
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algorithm based on pencil beam kernels is used to calculate dose images that will reflect the intended 
transmission distributions at the large focus-EPID distance in absence of a patient. In the case of in vivo 
dosimetry, the goal is to verify the dose actually delivered to a patient during treatment time [23]. 
 
The main advantages of in vivo dosimetry over pre-treatment verification include high resolution 
2D digital images available immediately after irradiation, very little additional clinical time, containing both 
dose and anatomical information, providing a check and documentation of the actual patient treatment (since 
measurements are acquired during treatment time), and the fact that the panel is already fixed to the LINAC. 
 
Either pre-treatment or in vivo dosimetry can be done using two different approaches: forward 
approach and backward approach. In the first approach (forward approach), the measured portal image is 
compared to a predicted dose, or photon fluence, at the plane of the EPID calculated with the treatment 
planning system (TPS), or by an independent dose calculation algorithm, while in the second approach 
(backward approach), a portal image is used to reconstruct the dose within the patient or phantom. This last 
method is more complicated but makes it possible to directly compare the calculated with the delivered dose 
distribution in the patient or phantom. A scheme illustrating the two different approaches can be seen in the 
figure below, Figure 2.7. 
 
 
Figure 2.7. The (a) forward and (b) backward approach for pre-treatment and in vivo dosimetry. Adapted from [25]. 
At the Radiotherapy Department of Champalimaud Foundation, there is forward projection EPD 
with an algorithm to calculate the dose at the level of EPID that is only used with plans that doesn’t have 
FFF (flattening filter free), and there is also back projection EPD. 
2.3.6 Back Projection Methods 
As mentioned before, portal dose images are not only useful to verify if the planned portal dose is 
identical to the measured portal dose, but they can also be used to make a full 3D reconstruction of the actual 
dose delivered to a patient using back projection methods. 
 
Back projection methods relate the primary portal dose with the dose effectively delivered to the 
patient. Therefore, is necessary to separate the primary portal dose, related with the radiologic thickness of 
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the path crossed by the photons in the patient, from the patient’s dispersed dose in EPID position, which 
comes from all the patient’s irradiated parts. In this way, a theoretical back projection method will describe 
the relationship between three types of data - 2 PDIs, one with and the other one without any object (i.e., 
phantom, if it is pre-treatment, or patient, if it is in vivo), and the radiologic thickness of the path crossed by 
the phantoms in the object - and must be able to extract the primary portal dose from a PDI measured during 
the treatment. Note that the radiologic thickness is related with the primary portal dose through the 
attenuation coefficient along the X-ray lines, and the prediction of a portal dose image is based in the 
assumption that the radiologic mean plan matches the isocenter plan. 
 
To sum up, back projection methods allow: 
• Dosimetric calibration to establish the dose-response relationship by relating EPID pixel values to 
dose values at the position of the imager; 
• Determination of the parameters for the back projection to enable the conversion from the dose at 
EPID position to the dose inside the patient or phantom. This is done by applying correction 
procedures for the scatter component of the dose within EPID and the scatter from the patient or 
photon to EPID; 
• Obtainment of the total dose at a specific point in the patient or phantom, taking in account the 
scatter component within the patient or phantom in combination with the attenuation beam. 
2.3.7 State of the Art 
Pre-Treatment Dosimetry  
Talamonti et. al [32], used a commercial amorphous silicon electronic portal imaging device (EPID) 
to investigate its potential in the field of pre-treatment verifications of step and shoot, intensity modulated 
radiation therapy (IMRT), 6 MV photon beams. The a-Si EPID demonstrated a good linearity with dose 
(within 2 % from 1 MU), which represent a pre-requisite for the application in IMRT. Ma et al. [33] 
employed a fast beam imaging system (BIS, Wellhöfer, Germany), and compared measured images with 
reference images generated from the MLC leaf sequencing files. Gross errors, such as flipped reference 
images, as well as positional errors of 0.5 mm in the leaf motion, were readily detected by the presented 
procedure. Curtin-Savard et al. [34] reported on the use of a liquid-filled portal imager for the dosimetric 
verification of step-and-shoot delivery by acquiring a portal image for every subfield of the leaf sequence. 
After their calibration, the images were multiplied by their respective associated monitor unit (MU) settings, 
and summed to produce a planar distribution at the measurement depth in a phantom. These distributions 
were then compared with dose distributions predicted by the TPS. Pasma et al. [35] reported on the use of 
a CCD-camera based fluoroscopic EPID for pre-treatment verification of intensity modulated beams 
produced with a DMLC. Due to the high data acquisition rate of these cameras, and their capability to 
measure simultaneously in all points of the treatment field, integrated images could be obtained. These 
images were then converted into two-dimensional dose distributions, and compared with the calculated dose 
distributions. For the reported profiles, the agreement between predictions and EPID measurements, and 
between ionization chamber measurements and EPID measurements, was within 2 % (1 SD). Chang et al. 
[36] developed a quality assurance procedure to assess the intensity profile, and dosimetry for intensity 
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modulated treatments fields, using a liquid-filled portal imaging device (PortalVision Mk1, Varian Medical 
Systems, Palo Alto, CA). To overcome the limited acquisition rate of their detector (5 s/image for the fast 
acquisition mode), the leaf speed was intentionally slowed down by drastically increasing the amount of 
MUs (which increased the treatment verification time, enabled the detection of any error influenced by the 
speed of the leaves and, therefore, led to an incomplete verification). Esch et. al [37] investigated the use of 
a commercially available, liquid-filled EPID (PortalVision Mk2, Varian Medical Systems) for dosimetric 
verification of intensity modulated beam profiles, delivered with a dynamic MLC, and concluded that 
accurate dosimetric images could be obtained. The dosimetric accuracy of the measured dose distribution 
was ∼2 % with respect to film and ion chamber measurements, and, when comparing the acquired and 
expected distributions, an overall agreement of 3 % was obtained. Years later, Esch et. al [21], investigated 
the basic dosimetric characteristics of an aSi portal imager (aS500, Varian Medical Systems), using an 
acquisition mode especially developed for portal dose (PD) integration during delivery of a static or 
dynamic- radiation field. Absolute rather than relative dose prediction was applied, and the PD image 
prediction was compared to the corresponding acquisition for several clinical IMRT fields by means of the 
gamma evaluation method. They concluded that, although the dose deposition behavior in the portal image 
detector was not equivalent to the dose to water measurements, it was reproducible and self-consistent, 
lending itself to quality assurance measurements. Gamma evaluations of the predicted versus measured 
portal dose distribution were within the pre-defined acceptance criteria for all clinical IMRT fields (i.e. 
allowed a dose difference of 3 % of the local field dose in combination with a distance to agreement of 
3mm). 
In vivo Dosimetry 
Nijsten et. al [38], used a calibrated camera-based EPID to measure the central field dose, which 
was then compared with a dose prediction at EPID level. For transit dosimetry, dose data was calculated 
using patient transmission and scatter, and compared with measured values. Furthermore, measured transit 
dose data was back-projected to an in vivo dose value at 5 cm depth in water (D5), and directly compared 
with D5 from the treatment planning system. The results showed that pre-treatment measurements had a 
mean dose difference per treatment session of 0.0 ± 1.7 % (1 SD), and in vivo measurements had a mean 
transit and a D5 dose differences of -0.7 ± 5.2 % (1 SD) and -0.3 ± 5.6 % (1 SD) per treatment session, 
respectively. Pasma et. al [39], proposed a method for in vivo verification of the MU calculation of the 
treatment beams. The method was based on comparison of the intended on-axis patient dose at 5 cm depth 
for each treatment beam, D5, with D5 as derived from the portal dose Dp measured with an EPID. The 
results obtained confirmed the accuracy of the method in verifying the MU calculation of an X- ray beam, 
and in discriminating errors that were due to changes in patient anatomy related to appearance or 
disappearance of gas pockets in the rectum, and errors due to a deviating cGy/MU value. Piermattei et. al 
[40], developed a method for the in vivo determination of the isocenter dose, Diso, and mid-plane dose, Dm, 
using the transmitted signal St measured by 25 central pixels of an aSi-based EPID. The method had been 
applied to check the conformal radiotherapy of pelvic tumors, and supplied accurate in vivo dosimetry, 
avoiding many of the disadvantages associated with the use of two diode detectors (at the entrance and exit 
of the patient) as their periodic recalibration and their positioning. The agreement between the in vivo 
dosimetry and stated doses at the isocenter point were within 3 %. One year later, for the first time, 
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Piermattei et. al [41], applied the method developed to brain and thorax irradiations using a transit signal 
St. The transit signal St was measured along the beam central axis by a small air ion-chamber, positioned 
on EPID, or by a last generation EPID. The method, that used correlation functions determined by the ratios 
between St and Dm measured in standard water-equivalent phantoms, was applied to determine Diso even 
in the presence of asymmetric inhomogeneities. The results showed that the tolerance/action levels for every 
radiotherapy fraction were 4 % and 5 % for the brain (symmetric inhomogeneities) and thorax/pelvic 
(asymmetric inhomogeneities) irradiations, respectively. In this way, the variations between the total 
measured and prescribed doses at the isocenter point in five fractions, were well within 2 % for the brain 
treatment, and 4 % for thorax/pelvic treatments. 
 
2.4 Dose Verification 
 
In pre-treatment patient-specific QA of IMRT and VMAT plans, dose verification is needed to avoid 
underdose of the target volume or overdose of the normal tissues. Thus, different methods that allow the 
efficient and accurate comparison between the calculated and the measure dose distribution, have been 
developed and used in clinical practice.  
2.4.1 Profile Comparison 
One method that is very useful when evaluating local deviations between dose distributions is the 
profile comparison. This consists in plotting, against each other, the evaluated and reference dose 
distributions proﬁles in the X, Y, or diagonal directions, to be visually compared.  
 
2.4.2 Distance-to-Agreement 
The distance-to-agreement (DTA) consists in measuring the spatial difference between a point in 
the reference dose distribution, 𝑟𝑟⃗⃗  , and the closest point with the same dose value in the evaluated dose 
distribution, 𝑟𝑒⃗⃗⃗  , such that, 
 
Γ(𝑟𝑟,⃗⃗⃗⃗ 𝑟𝑒⃗⃗⃗  ) = 𝑚𝑖𝑛|𝑟𝑒⃗⃗⃗  − 𝑟𝑟 ⃗⃗⃗⃗ | (Equation 2.3) 
 
Usually, a threshold value of ∆𝑑, typically ∆𝑑 = 3𝑚𝑚, is considered as acceptance criteria in a way 
that if the DTA at the evaluated point 𝑟𝑒⃗⃗⃗   is higher than ∆𝑑, the DTA criterion fails, otherwise, if the DTA at 
the evaluated point 𝑟𝑒⃗⃗⃗   is lower than ∆𝑑, the DTA criterion passes [28]. 
 
2.4.3 Gamma Evaluation 
Nowadays, the gold standard method for the evaluation of comparisons between measured and 
calculated absorbed dose distributions is the so-called gamma evaluation method. 
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The gamma method was designed by Low et al [28] to compare two dose distributions. In this, one 
dose distribution is used as reference (Dr), while the other is used for evaluation (Dc), taking in account the 
dose and spatial differences between them. Thus, the gamma evaluation method is a tool that allows the 
comparison of dose distributions on a quantitative manner by combining dose difference (DD) and distance-
to-agreement (DTA) criteria to determine if the compared dose points pass or fail the dose distribution 
comparison test.  
 
The acceptance criterion is denoted by ∆DM (measured in %) for DD, and by ∆dM (measured in 
mm) for DTA, and is usually 3 %, 3 mm (once IMRT dose distributions often dose gradients of close to 
3%/3 mm). The evaluation is performed for each point in the reference dose distribution, 𝑟𝑟⃗⃗  , to ﬁnd the most 
similar point in the evaluated dose distribution, 𝑟𝑒⃗⃗⃗  , and provides a numerical quality index, referred to as 
gamma value or gamma index. The gamma index is basically a measure of agreement or disagreement in 
regions that pass or fail the acceptance criteria, respectively, reflecting the calculation quality in these 
regions [29]. 
 
For 2D dose distributions, the gamma method is denoted by an ellipsoid surface (Figure 2.8) 
representing the acceptance criteria for dose and spatial tolerance with the center located at 𝑟𝑟⃗⃗  , 
 
Γ(𝑟𝑟,⃗⃗⃗⃗ 𝑟𝑒⃗⃗⃗  ) = √
𝑟2(𝑟𝑟,⃗⃗ ⃗⃗  𝑟𝑒⃗⃗  ⃗)
Δ𝑑𝑀
2 +
𝛿2(𝑟𝑟,⃗⃗ ⃗⃗  𝑟𝑒⃗⃗  ⃗)
Δ𝐷𝑀
2  (Equation 2.4) 
 
where 𝑟2(𝑟𝑟,⃗⃗⃗⃗ 𝑟𝑒⃗⃗⃗  ) is the spatial distance between the evaluated point, 𝑟𝑒⃗⃗⃗  , and the reference point, 𝑟𝑟⃗⃗  , 
i.e., 𝑟2(𝑟𝑟,⃗⃗⃗⃗ 𝑟𝑒⃗⃗⃗  ) = |𝑟𝑒⃗⃗⃗  − 𝑟𝑟 ⃗⃗⃗⃗ |, and 𝛿
2(𝑟𝑟,⃗⃗⃗⃗ 𝑟𝑒⃗⃗⃗  ) is the dose difference between the evaluated dose 𝐷𝑒, at position 
𝑟𝑒⃗⃗⃗  , and the reference dose 𝐷𝑟, at position 𝑟𝑟⃗⃗  , i.e., 𝛿
2(𝑟𝑟,⃗⃗⃗⃗ 𝑟𝑒⃗⃗⃗  ) = |𝐷𝑒(𝑟𝑒⃗⃗⃗  ) − 𝐷𝑟(𝑟𝑟 ⃗⃗⃗⃗ )|. The gamma index is then 
calculated by finding the minimum value of Γ(𝑟𝑟,⃗⃗⃗⃗ 𝑟𝑒⃗⃗⃗  ) so that, 
 
γ(𝑟𝑟⃗⃗  ) = min{Γ(𝑟𝑟,⃗⃗⃗⃗ 𝑟𝑒⃗⃗⃗  )}, ∀ {𝑟𝑒⃗⃗⃗  } (Equation 2.5) 
 
Finally, for the compared distribution to match, the gamma value for the reference dose at position 
𝑟𝑟 ⃗⃗⃗⃗  must be equal or smaller than 1. Otherwise, i.e., if γ(𝑟𝑟⃗⃗  ) > 1, we can conclude that the evaluated point 
𝑟𝑒⃗⃗⃗   is not within the speciﬁed acceptance criterion [29]. 
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Figure 2.8. Geometric representation of the theoretical concept of the gamma evaluation method for 2D dose distributions. 
In this example, the evaluated point, 𝒓𝒆⃗⃗⃗⃗  , fails the criterion. Retrieved from [29]. 
The most common approach is based on the use of a global criterion for DD, where ∆𝐷𝑀 is constant 
for all points evaluated and calculated regarding the maximum dose. When instead of using a global criterion 
for DD, a local criterion for DD is used (∆𝐷𝑀 not constant and calculated regarding the dose at the reference 
point), a stricter constraint should be use. 
 
It is important to note that, due to the unavoidable uncertainties of absorbed dose measurements and 
detector positioning, some points in the gamma evaluation may fail the test criteria even if there is no true 
deviation and, therefore, a certain failure rate should be tolerated.  
 
Compared to dose difference, the gamma evaluation is less sensitive to spatial deviation to the 
imager from the optimal position. For this reason, gamma image is the main source for statistic evaluation 
but it is not suited for alignment because of the principle of the underlying algorithm, which, as mentioned 
before, allows a certain spatial deviation. However, it can be used for virtual inspection of the degree of 
agreement between predicted and measured dose after alignment. 
 
In the case of Portal Dosimetry (portal dose image prediction) software, i.e., the Varian software 
available for portal dosimetry, when applying the gamma evaluation method, we obtain a measure called 
gamma passing rate – a value between 0 % and 100 % - which will reflect the success/failure of the 
irradiation plan. In other words, the magnitude of the gamma passing rate will correspond to the dose 
discrepancy between the planned dose and the actual delivered dose for a given plan.  
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CHAPTER 3. MATERIALS AND METHODS 
As said previously, in the Radiotherapy Department of the of the Champalimaud Foundation, there 
are two different Varian LINAC, TrueBeam™ and Edge™ (Varian Medical Systems, Palo Alto, CA, USA), 
that have different a-Si EPIDs incorporated in the retractable robotic arm – aS1000 and aS1200, 
respectively, with different characteristics (Erro! A origem da referência não foi encontrada.). To perform 
pre-treatment dosimetry for both IMRT and VMAT plans, Varian had developed a Portal Dose Image 
Prediction Algorithm and a Portal Dosimetry software inside the ARIA® interface. 
 
 TrueBeam™ Edge™ 
PortalVision aS1000 aS1200 
Active Matrix Area 30 cm x 40 cm 43 cm x 43 cm 
Pixel Number 1024 pixel x 768 pixel 1280 pixel x 1280 pixel 
Pixel Size 0.39 mm x 0.39 mm 0.34 mm x 0.34 mm 
Maximum Frame Rate 10 frames per second 25 frames per second 
Maximum Dose Rate 1000 MU/min 5000 MU/min 
Table 3.1. Characteristics of the different Varian LINAC EPIDs. 
 
In the next figures, Figure 3.1 and Figure 3.2, we can see the TrueBeam™ and Edge™ LINAC, 
without and with EPID opened, respectively. 
 
 
Figure 3.1. TrueBeam™ LINAC (a) without and (b) with EPID (red arrow) opened. 
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Figure 3.2. Edge™ System (a) without and (b) with EPID (red arrow) opened. 
In Figure 3.3, we can see ArcCHECK, from both sides, as well as ArcCHECK mounted on the 
Edge™ LINAC. 
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Figure 3.3. ArcCHECK viewed from (a) the front part and from (b) the back part, and (c) mounted on the LINAC. Note 
that in order to place ArcCHECK correctly, we have to align the lasers with ArcCHECK marks, and then with the light 
field. 
3.1 Varian Portal Dosimetry Solution 
 
The Varian Portal Dosimetry solution includes an EPID, a Portal Image Dose Prediction (PDIP) 
algorithm, and a Portal Dosimetry software. The EPID can be one of three a-Si models: PortalVision aS500, 
aS1000 or aS1200. The PDIP algorithm is a dedicated 2D-algorithm to predict the portal dose image that 
will be the first clinical VMAT verification. Finally, the Portal Dosimetry software allows the comparison 
(gamma evaluation) between predicted and portal dose images acquired by EPID (see Figure 3.4). 
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Figure 3.4. Portal Dosimetry workspace. 
 
Regarding the Portal Dosimetry workspace shown in Figure 3.4, we can see the portal dose image 
acquired with EPID (in the upper right side) and the correspondent portal dose image predicted by the PDIP 
algorithm (in the upper left side). The acquired and the predicted portal dose images are automatically 
blended resulting in the portal dose image sown in the center. After the analysis, the results appear in the 
white box, and the profiles along collimator x and y for both images, as well as a dose difference histogram, 
are displayed. In this case, the acquired portal dose image is nearly indistinguishable from the correspondent 
predicted dose, resulting in a gamma passing rate of 99.4 % for the 3 %/3 mm criterion. It is important to 
note that the evaluated area is the complete irradiation area outline (CIAO). 
 
In the next figures, Figure 3.5 and Figure 3.6, we can see in more detail the profiles along 
collimator x and y for another acquired and predicted portal dose images, as well as a gamma evaluation 
histogram of the composite portal dose image (result of the combination of the portal dose images obtained 
for each arc of the plan), respectively. 
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Figure 3.5. Profiles along collimator x (blue and red lines) and y (green and yellow lines) for acquired (blue and green lines) 
and predicted (red and yellow lines) portal dose images. 
 
 
 
Figure 3.6. Gamma evaluation histogram of the composite portal dose image. 
 
Regarding the main purpose of this work – replace ArcCHECK QA measurements and bring into 
the clinic the routinely use of EPID to perform QA measurements – different studies were conducted:  
• Study A: On the TrueBeam™ LINAC, the performance of the Portal Dosimetry solution for pre-
treatment patient-specific QA of IMRT and VMAT plans was compared with ArcCHECK; 
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• Study B: On the Edge™ LINAC, the performance of the Portal Dosimetry solution for pre-
treatment patient-specific QA of IMRT and VMAT plans was compared with the performance of 
the same solution on the TrueBeam™ LINAC;  
• Study C: On the Edge™ LINAC, the performance of the Portal Dosimetry solution for pre-
treatment patient-specific QA of IMRT and VMAT plans was compared with ArcCHECK; 
• Study D: On the Edge™ LINAC, errors were introduced in the patient plans in order to study the 
sensitivity of EPID during pre-treatment patient-specific QA 
• Study E: On the Edge™ LINAC, errors were introduced in the patient plans to study the sensitivity 
of ArcCHECK during pre-treatment patient-specific QA, and the sensitivity of both ArcCHECK 
and EPID systems was compared; 
• Study F: Finally, on the Edge™ LINAC, a software was developed in order to export the patient 
plans with errors into the ARIA® interface and evaluate the effects of the different types of error in 
the organs at risk, to see whether clinically relevant errors would be detected with 
EPID/ArcCHECK. 
 
All the measurements, in each one of the studies mentioned before, were performed with non-transit 
dosimetry at EPID level (EPID at 100 cm), according to the speciﬁcations of the EPID attached to each 
Varian LINAC in the Radiotherapy Department of Champalimaud Foundation (TrueBeam™ and Edge™ 
systems).  
 
3.2 Data Sets 
3.2.1 Study A 
In the first study, Study A, the aim was to compare the gamma passing rates values obtained when 
performing pre-treatment patient-specific QA with ArcCHECK and with EPID, on the TrueBeam™ 
LINAC, in order to prove that EPID is as good, or even better than ArcCHECK. For that, 163 anonymized 
6 MV IMRT and VMAT patient plans were irradiated on the TrueBeam™ LINAC (from September 2016 
to November 2016) for both ArcCHECK and EPID systems (see Table 3.2). 
 
In an initial phase, the patients were selected and previously planned using Eclipse. Once planned 
and scheduled, each patient plan was tested a priori on the TrueBeam™ LINAC available at the 
Radiotherapy Department of the Champalimaud Foundation. Finally, after the irradiation, using the Portal 
Dosimetry software (version 10), the portal imagens obtained from the irradiation were analysed and 
compared with the predictions, in order to make a comparison between the prescribed dose and the dose 
actually given, as well as a gamma passing rate evaluation. The results obtained with the EPID system were 
then compared with the ones obtained previously with ArcCHECK. It is important to notice that, to avoid 
bias, we have included both rejected and accepted patient plans after performing pre-treatment patient-
specific QA with ArcCHECK, i.e., both patient plans with a gamma passing rate below and above 90 %, 
respectively (when we have 90 % or more of the points with gamma < 1, we plan is accepted; otherwise, 
the plan is rejected). If we had only considered patient plans accepted after performing pre-treatment patient-
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specific QA with ArcCHECK, we would be conditioning the results once we would be only considering the 
ones that had a good gamma passing rate and, therefore, the ones that probably had also a good gamma 
passing rate after performing pre-treatment patient-specific QA with EPID. In the analysis of the results, a 
gamma criterion of 3 %/3 mm was used, and two thresholds of 90 % and 95 % were considered. 
Table 3.2. Information correspondent to the treatment course and dose per fraction for each one of the 163 patients 
included in the first study, Study A. 
# Patients Treatment Course  Dose per Fraction (Gy) 
50 Thorax (6) 
(43) 
(1) 
2.7 
3.2 
3.4 
112 Pelvis (1) 
(10) 
(101) 
1.8 
2.25 
2.5 
1 Member  1.8 
 
3.2.2 Study B 
The second study, Study B, which aimed to compare the average gamma values, as well as the 
average dose difference values, obtained when performing pre-treatment patient-specific QA with EPID, 
for two different LINACs (TrueBeam™ LINAC and Edge™ LINAC), included 16 anonymized 6 MV 
IMRT and VMAT prostate and breast patient plans (irradiated on October 2016). The analysis software 
used (Portal Dosimetry version 10) was the same in both cases (see Erro! A origem da referência não foi 
encontrada.). 
 
The method used in this study was the same as the one mentioned for the Study A with the difference 
that, this time, each patient plan was irradiated on both TrueBeam™ and Edge™ LINAC in order to compare 
the two LINACs used. In the analysis of the results, a gamma criterion of 3 %/3 mm was used. 
 
Table 3.3. Information correspondent to the treatment course and dose per fraction for each one of the 16 patients 
included in the second study, Study B. 
 
# Patients Treatment Course  Dose per Fraction (Gy) 
6 Thorax (2) 
(3) 
(1) 
2.7 
3.2 
3.4 
10 Pelvis  2.25 
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3.2.3 Study C 
The aim of the third study, Study C, was, like the Study A, to compare the gamma passing rates 
values obtained when performing pre-treatment patient-specific QA with ArcCHECK and with EPID, on 
the Edge™ LINAC, in order to prove that EPID is as good, or even better, than ArcCHECK. For that, 91 
anonymized IMRT and VMAT patient plans were irradiated on the Edge™ LINAC (from December 2017 
to February 2017). Unlike the previous studies, this study included patient plans with both 6 MV and FFF 
beams (see Table 3.4). 
 
The method used for this study was the same as the one described in the previous studies, with the 
difference that, while in Study A, the thorax patients were mainly breast patients, in this study, the thorax 
patients were mainly lung patients. In the analysis of the results, a gamma criterion of 3 %/3 mm was used, 
and two thresholds of 90 % and 95 % were considered. 
 
Table 3.4. Information correspondent to the treatment course and dose per fraction for each one of the 91 patients 
included in the third study, Study C. 
# Patients Treatment Course  Dose per Fraction (Gy) 
32 Thorax (1) 
(9) 
(3) 
(2) 
(16) 
(1) 
7 
8 
9 
22 
24 
26 
36 Pelvis (3) 
(1) 
(1) 
(3) 
(1) 
(5) 
(4) 
(1) 
(17) 
5 
6.5 
6.7 
7 
7.5 
8 
9 
10 
24 
13 Abdomen (3) 
(1) 
(1) 
(8) 
8 
10 
18 
24 
2 Member  8 
8 Brain (1) 
(1) 
(1) 
4 
7 
10 
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(1) 
(4) 
18 
24 
1 Head & Neck  7 
 
3.2.4 Study D 
In the fourth study, Study D, the aim was to introduce errors in the XML files (plain text files that 
describe the transportation, structure, and storage of data) with the patient plans to test the sensitivity of 
EPID incorporated on the Edge™ LINAC, i.e., in order to verify if there is any relationship between the 
values of the average gamma and the magnitude of the error introduced. Four different types of error were 
introduced - errors in the MUs, errors in the MLC position (random and systematic), and errors in the 
collimator angle. For that, 4 anonymized FFF IMRT and VMAT patient plans were irradiated (on November 
2016) on the Edge™ LINAC (see Table 3.5). 
 
Unlike the three previous studies, in an initial phase, the patient plans were converted in XML files. 
Then, using the ReadDCMPlan software, different types of error were introduced for the four different 
patients. Once introduced the errors in the XML files, the files were transferred into the Edge™ LINAC, to 
irradiate the plans. Finally, after the irradiation, the portal images obtained were stored in the data base, and 
downloaded in the Varian Citrix. In this platform, using the Portal Dosimetry software (version 13) and 
converting the images to DICOM files according to each magnitude of error introduced, for each arc, and 
for each patient, the portal images were analysed and compared with the ones from the CT, in order to make 
a comparison between the prescribed dose and the dose actually given, as well as an average gamma 
evaluation. In the analysis of the results, a gamma criterion of 3 %/3 mm was used. 
 
Table 3.5. Information correspondent to the treatment course and dose per fraction for each one of the 4 patients included 
in the fourth study, Study D. 
# Patients Treatment Course  Dose per Fraction (Gy) 
1 Pelvis  2 
2 Brain (1) 
(1) 
10 
18 
1 Head & Neck  46 
 
3.2.5 Study E 
The fifth study, Study E, aimed introduce errors in the XML files in order to test the sensitivity of 
both EPID and ArcCHECK. Four different types of error were introduced - errors in the MUs, errors in the 
MLC position (random and systematic), and errors in the collimator angle – in four different chosen patients. 
This fifth study included 7 anonymized FFF IMRT and VMAT patient plans that were irradiated (on May 
2017) on the Edge™ LINAC (see Table 3.6). 
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Since we were testing the sensitivity of the ArcCHECK system as well, we had to introduce errors 
in the patient plans. The way we found to do so included, in an initial phase, converting the patient plans in 
XML files. Then, using the ReadDCMPlan software, different types of error were introduced for the three 
different patients. Once introduced the errors in the XML files, the files were converted to a DICOM format 
to import them into the ARIA® interface. After this, the files were transferred into the Edge™ LINAC, to 
be possible to irradiate the plans. Finally, after the irradiation, the portal images obtained were stored in the 
data base, and downloaded in the Varian Citrix. In this, using the Portal Dosimetry software (version 13) 
and converting the images to DICOM files according to each magnitude of error introduced, for each arc, 
and for each patient, the portal images were analysed and compared with the prescribed, in order to make a 
comparison between the prescribed dose and the dose actually given, as well as an average gamma 
evaluation. In the analysis of the results, a gamma criterion of 3 %/3 mm was used. 
 
Table 3.6. Information correspondent to the treatment course and dose per fraction for each one of the 7 patients 
included in the fifth study, Study E. 
 
# Patients Treatment Course  Dose per Fraction (Gy) 
5 Thorax (1) 
(1) 
(2) 
(1) 
2.25 
20 
24 
27 
2 Pelvis (1) 
(1) 
2 
5 
 
3.2.6 Study F 
Finally, the aim of the sixth and last study, Study F, was to introduce errors in the XML files and 
export the plans with errors into the ARIA® interface in order to compare the plans with errors with the 
ones without errors and, therefore, verify the effect of the errors in the organs at risk. For that, 1 anonymized 
FFF IMRT patient plan was irradiated (on June 2016) on the Edge™ LINAC (see Table 3.7).  
 
The procedure used in the study was the same as the one used in the previous study with the 
difference that, after introducing errors in the XML file, transferring the file into the Edge™ LINAC, and 
irradiating the plan, the plan with errors was exported into the ARIA® interface, using ReadDCMPlan 
software. After exporting the XML files back to the ARIA® interface, the principal organs at risk were 
selected, and its dose constraints checked. Then, using the External Beam Planning software, the dose 
volume histograms (DVHs) for each organ at risk selected were analysed. Finally, the volume difference 
between the reference volume (with zero error) and the volume verified was calculated for each magnitude 
error, and the graphics regarding this difference, were obtained. In the analysis of the results, three gamma 
criteria of 1 %/1 mm, 2 %/2 mm, and 3 %/3 mm, were used. 
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Table 3.7. Information correspondent to the treatment course and dose per fraction for the patient included in the 
sixth study, Study F. 
 
# Patients Treatment Course  Dose per Fraction (Gy) 
1 Thorax (1) 2.66 
 
3.2.7 DICOM format 
Digital imaging and communication in medicine (DICOM) is the standard format used for 
management of medical imaging and related data, as well as for communication between different types of 
medical imaging devices and the computer. DICOM-RT is an extension of the DICOM that is speciﬁed for 
radiotherapy modality and it includes different type of information: (1) DICOM-RT Structure, which 
describes all the different structures delineated from the planning CT; (2) DICOM-RT Plan, which includes 
information related to the treatment beams conﬁguration, collimator geometric conﬁguration, and dose 
prescription; (3) DICOM-RT Dose, which describes the dose distributions calculated; and (4) DICOM-RT 
Image, which includes the images acquired during the treatment and their related information. 
 
3.2.8 XML file 
Extensible markup language (XML) is a markup language that defines a set of rules for encoding 
documents in a format that is both human-readable and machine-readable, by using tags that can be created 
and defined by users. XML is specially used to annotate text or additional information, i.e., to outsource 
data. 
3.2.9 ReadDCMPlan 
In order to introduce errors in the patient plans, send the patient plans to the LINAC in order to 
irradiate them, and send them back to the ARIA® interface after irradiation on the LINAC, a software called 
ReadDCMPlan was developed on the Radiotherapy Department Champalimaud Foundation. 
 
ReadDCMPlan acts on four levels: 
1. First, the software reads the patient plan, in DICOM, from the ARIA® interface; 
2. Then, the software allows the user to alter the plan parameters by introducing different types of 
error (MUs, MLC position, and collimator angle); 
3. After introducing errors, the software converts the DICOM files with the patient plans, into 
XML files. These XML files can then be transferred to the LINAC and irradiated on it; 
4. Finally, after irradiation, the resultant XML files (with the result of the radiation) can be 
transferred to the ARIA® interface. For that, the software converts the XML files into DICOM 
files, format readable by the TPS. 
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CHAPTER 4. RESULTS AND DISCUSSION 
4.1 TrueBeam™ LINAC 
4.1.1 QA ArcCHECK vs QA EPID 
In the first study, Study A, as mentioned before, the aim was to compare the gamma passing rates 
values obtained when performing pre-treatment patient-specific QA with ArcCHECK and with EPID, on 
the TrueBeam™ LINAC, in order to prove that EPID is as good, or even better, than ArcCHECK.  
 
In the first graph, Figure 4.1, we see the gamma passing rate values obtained for the composite 
image, after performing pre-treatment patient-specific QA with ArcCHECK, against the gamma passing 
rate values obtained after performing pre-treatment patient-specific QA with EPID. Both measurements 
were made on the TrueBeam™ LINAC. The composite image is the result of the combination of the portal 
images obtained for each arc of the plan. 
 
 
Figure 4.1. Composite gamma passing rate values obtained after performing pre-treatment patient-specific QA with 
ArcCHECK, against the gamma passing rate values obtained after performing pre-treatment patient-specific QA with 
EPID. The results were analysed with a 3 %/3 mm gamma criterion. The red line corresponds to the 90 % threshold, while 
the orange line corresponds to the 95 % threshold. 
In the second graphic, Figure 4.2, we see the same data as the one shown in Figure 4.1, but, this 
time, separated by type of patient. 
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Figure 4.2. Composite gamma passing rate values obtained after performing pre-treatment patient-specific QA with 
ArcCHECK, against the gamma passing rate values obtained after performing pre-treatment patient-specific QA with 
EPID, on the TrueBeam™ LINAC, separated by type of patient. The results were analysed with a 3 %/3 mm gamma 
criterion. The red line corresponds to the 90 % threshold, while the orange line corresponds to the 95 % threshold. 
 
From the analysis of Figure 4.1, and for the 140 patient plans approved after performing pre-
treatment patient-specific QA with ArcCHECK, we conclude that ArcCHECK allows better results when 
compared with EPID, once we don’t have any gamma passing rate value below 90 % for ArcCHECK, and, 
for EPID, we have a few. Regarding the 23 patient plans that weren’t approved after performing pre-
treatment patient-specific QA with ArcCHECK, we conclude that we have higher gamma passing rates 
when using EPID and, for all cases, the plans that were rejected after performing pre-treatment patient-
specific QA with ArcCHECK (due to the gamma passing rate below 90 %) weren’t rejected after performing 
pre-treatment patient-specific QA with EPID. 
 
Regarding Figure 4.2, we can see that we have better results for the thorax patients (higher gamma 
passing rate values), breasts mainly, and worse results for the pelvis patients, prostates mainly. This can be 
explained by the size of the fields once, for the thorax patients, we usually have bigger fields than for the 
pelvis patients. Other reason for this can be the different techniques used once for the thorax patients we use 
IMRT and, for the pelvis patients, we use VMAT. Also, this difference can also be related with the segments, 
i.e., the plans of the pelvis patients can have higher number of segments than the plans of the thorax patients, 
explaining the better values obtained for the thorax patients. Finally, another strong hypothesis would be 
the PDIP algorithm calibrated incorrectly. 
 
It is important to note that most of the results regarding ArcCHECK were already obtained by the 
time I got at Champalimaud Foundation (due to the pre-treatment patient-specific QA needed and performed 
with ArcCHECK before each patient treatment), and that the results obtained regarding EPID were only 
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obtained by me during my project. Thus, the time interval between the different types of measurement can 
potentially explain some of the differences that we see once there are many factors such as changes on the 
LINAC output, or changes with the successive interventions and maintenances on the LINAC, that can 
affect some parameters of the LINAC and, therefore, the measurements performed. 
Statistical Data Analysis 
Regarding the results obtained, a statistical data analysis was performed using the t-Student test. 
The t-student test is a statistical test in which the test statistic (t) follows a Student’s t-distribution under the 
null hypothesis [42]. 
 
For that, two samples were considered – the one with the measurements performed on ArcCHECK, 
A, and the one with the measurements performed on EPID, E -, and two different variables were defined – 
the gamma passing rate obtained for the measurements performed on ArcCHECK, 𝑋𝐴, with a sample mean 
µ𝐴, and the gamma passing rate obtained for the measurements performed on EPID, 𝑋𝐸, with a sample mean 
µ𝐸. The following hypothesis were formulated: 
 
H0:   The results obtained in the two samples are equal, i.e.,  µ𝐴 = µ𝐸 
H1:   The results obtained for the sample E are better than the ones obtained for the sample A, i.e.,  
µ𝐴 < µ𝐸 
 
Thus, in this case, we have a left unilateral t-test, meaning that we will reject the H0 hypothesis if 
the critic value is higher than the statistic value obtained, i.e., if 𝑡 < −𝑡𝑐𝑟𝑖𝑡𝑖𝑐 , and we won’t reject the H0 
hypothesis if the critic value is lower than the statistic value obtained, i.e., if 𝑡 > −𝑡𝑐𝑟𝑖𝑡𝑖𝑐. 
 
Using the Excel Data Analysis, and choosing a significance level of 1 %, we could obtain the results 
shown in Table 4.1. 
 
Table 4.1. Results obtained after performing the t-Student test using the Excel Data Analysis.  
 
  𝑋𝐴 𝑋𝐸 
Média 97.0 97.7 
Variância 4.6 8.8 
Observações 59 59 
Hipótese de diferença de média 0  
gl 105  
Stat t -1.4  
P(T<=t) uni-caudal 0.1  
t crítico uni-caudal 2.4  
P(T<=t) bi-caudal 0.2  
t crítico bi-caudal 2.6  
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Looking for the value obtained for the statistic value 𝑡, -1.4, and for the critic value 𝑡𝑐𝑟𝑖𝑡𝑖𝑐, 2.4, we 
can conclude that 𝑡 > −𝑡𝑐𝑟𝑖𝑡𝑖𝑐 and, therefore, we can’t reject the H0 hypothesis with a level of significance 
of 1 %. In other words, the H0 hypothesis isn’t rejected since the value of P for  𝑡 = −1.4  is  𝑃 = 0.1 >
0.01 which is the significance level chosen. This means that the results obtained for the measurements 
performed on ArcCHECK (sample A) are better than the ones obtained for the measurements performed on 
EPID (sample E).  
 
4.2 TrueBeam™ LINAC vs Edge™ LINAC 
The second study, Study B, aimed compare the average gamma values, as well as the average dose 
difference values, obtained when performing pre-treatment patient-specific QA with EPID on the two 
different LINACs (TrueBeam™ LINAC and Edge™ LINAC), with the same plans. 
 
In the first two graphics, Figure 4.3 (a) and (b), we see the average gamma values (no units) 
obtained for each thorax (breast) and pelvis (prostate) patient, respectively, after performing pre-treatment 
patient-specific QA with EPID on the TrueBeam™ LINAC, against the average gamma values obtained for 
each prostate (VMAT plans) and breast (IMRT plans) patient, respectively, after performing pre-treatment 
patient-specific QA with EPID on the Edge™ LINAC. Note that, the values shown correspond to the values 
obtained after analysing the composite image.  
 
 
Figure 4.3. Composite average gamma values (no units) obtained for each (a) thorax and (b) pelvis patient, after performing 
pre-treatment patient-specific QA with EPID on the TrueBeam™ LINAC, against the average gamma values obtained for 
the same patient, after performing pre-treatment patient-specific QA with EPID on the Edge™ LINAC. The results were 
analysed with a 3 %/3 mm gamma criterion. 
(a) (b) 
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In the next two graphics, Figure 4.4 (a) and (b), we have the values of the average dose difference 
(CU units, being 1 CU = 1 cGy) obtained for each thorax and pelvis patient, respectively, after performing 
pre-treatment patient-specific QA with EPID on the TrueBeam™ LINAC, against the values of the average 
gamma obtained for each thorax and pelvis patient, respectively, after performing pre-treatment patient-
specific QA with EPID on the Edge™ LINAC. Note that, again, the values shown correspond to the values 
obtained after analysing the composite image. 
 
 
Figure 4.4. Composite average dose difference values, in CU, obtained for each (a) thorax and (b) pelvis patient, after 
performing pre-treatment patient-specific QA with EPID on the TrueBeam™ LINAC, against the values of the average 
gamma obtained for the same patient, after performing pre-treatment patient-specific QA with EPID on the Edge™ LINAC. 
 
Finally, in the next two graphics, Figure 4.5 (a) and (b), we have the values of the gamma passing 
rate obtained for each thorax and pelvis patient, respectively, after performing pre-treatment patient-specific 
QA with EPID on the TrueBeam™ LINAC, against the values of the average gamma obtained for each 
thorax and pelvis patient, respectively, after performing pre-treatment patient-specific QA with EPID on the 
Edge™ LINAC. The values shown correspond to the values obtained after analysing the composite image. 
 
(a) (b) 
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Figure 4.5. Composite gamma passing rate values obtained for each (a) thorax and (b) pelvis patient, after performing pre-
treatment patient-specific QA with EPID on the TrueBeam™ LINAC, against the values of the gamma passing rate obtained 
for the same patient, after performing pre-treatment patient-specific QA with EPID on the Edge™ LINAC. The results 
were analysed with a 3 %/3 mm gamma criterion. 
 
From the analysis of Figure 4.3 (a) and (b), and Figure 4.4 (a) and (b), we conclude that, for both 
thorax and pelvis patients, the results regarding the average gamma are better (lower values) for the Edge™ 
LINAC, while the results regarding the average dose difference are better (lower values) for the 
TrueBeam™ LINAC. Thus, the Edge™ LINAC allows better values in terms of average gamma, while the 
Edge™ LINAC, allows better results in terms of average dose difference. This can be explained by the 
different a-Si EPIDs incorporated on the two LINACs – the Edge™ LINAC has probably a better EPID 
than the TrueBeam™ LINAC.  
 
When we analyse the results in terms of gamma passing rate, Figure 4.5 (a) and (b), we can 
conclude that, for both thorax and pelvis patients, we have better results for the Edge™ LINAC. Once again, 
this can be explained by the better a-Si EPID incorporated in the Edge™ LINAC. 
4.3 Edge™ LINAC 
4.3.1 QA ArcCHECK vs QA EPID 
The aim of the third study, Study C, was, like the first study, to compare the gamma passing rates 
values obtained when performing pre-treatment patient-specific QA with ArcCHECK and with EPID, on 
the Edge™ LINAC, in order to prove that EPID is as good, or even better, than ArcCHECK.  
 
In the first graph, Figure 4.6, we see the gamma passing rate values obtained for the composite 
image, after performing pre-treatment patient-specific QA with ArcCHECK, against the gamma passing 
(a) (b) 
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rate values obtained after performing pre-treatment patient-specific QA with EPID. Both measurements 
were made on the Edge™ LINAC. 
 
  
Figure 4.6. Composite gamma passing rate values obtained after performing pre-treatment patient-specific QA with 
ArcCHECK, against the gamma passing rate values obtained after performing pre-treatment patient-specific QA with 
EPID, on the Edge™ LINAC. The results were analysed with a 3 %/3 mm gamma criterion. The red line corresponds to the 
90 % threshold, while the orange line corresponds to the 95 % threshold. 
 
In the next graphic, Figure 4.7, we see the same data as the one shown in the Figure 4.6, separated 
by type of patient. 
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Figure 4.7. Composite gamma passing rate values obtained after performing pre-treatment patient-specific QA with 
ArcCHECK, against the gamma passing rate values obtained after performing pre-treatment patient-specific QA with 
EPID, on the Edge™ LINAC, separated by type of patient. The results were analysed with a 3 %/3 mm gamma criterion. 
The red line corresponds to the 90 % threshold, while the orange line corresponds to the 95 % threshold. 
 
From the analysis of Figure 4.6, and for both patient plans approved and rejected after performing 
pre-treatment patient-specific QA with ArcCHECK, we conclude that EPID allows much better results when 
compared with ArcCHECK, once we don’t have any gamma passing rate value below 90 % for EPID, and 
for ArcCHECK we have some. This means that all the plans rejected with ArcCHECK were approved with 
EPID. 
 
Regarding Figure 4.7, we can see that, with ArcCHECK, we have better results for thorax patients 
(higher gamma passing rate values), and worse results for pelvis patients. This can be explained by the size 
of the fields once, for thorax patients, we usually have bigger fields than for pelvis patients. This would be 
probably the stronger reason. Other difference can be related with the number of segments, i.e., the plans of 
pelvis patients can have higher number of segments than the plans of thorax patients, explaining the better 
values obtained for thorax patients. 
 
Once again it is important to note that most of the results regarding ArcCHECK were already 
obtained by the time I got at Champalimaud Foundation, and that the results obtained regarding EPID were 
only obtained by me during my project. Thus, the time interval between the different types of measurement 
can potentially explain some of the differences that we see once there are many factors such as changes on 
the LINAC output, or changes with the successive interventions and maintenances on the LINAC, that can 
affect some parameters of the LINAC and, therefore, the measurements performed. 
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Statistical Data Analysis 
Regarding the results obtained, in the same way as for Study A, a statistical data analysis was 
performed using the t-Student test (Excel Data Analysis), and choosing a significance level of 1 % (see 
Table 4.2) [42]. 
 
Table 4.2. Results obtained after performing the t-Student test using the Excel Data Analysis. 
 𝑋𝐴 𝑋𝐸 
Média 95.9 99.4 
Variância 12.7 0.8 
Observações 91 91 
Hipótese de diferença de média 0  
gl 101  
Stat t -9.0  
P(T<=t) uni-caudal 0.0  
t crítico uni-caudal 2.4  
P(T<=t) bi-caudal 0.0  
t crítico bi-caudal 2.6  
 
Looking for the value obtained for the statistic value t, -9.0, and for the critic value 𝑡𝑐𝑟𝑖𝑡𝑖𝑐, 2.4, we 
can conclude that  𝑡 < −𝑡𝑐𝑟𝑖𝑡𝑖𝑐 and, therefore, we reject the H0 hypothesis with a level of significance of 1 
%. In other words, the H0 hypothesis is rejected since the value of P for  𝑡 = −9.0  is  𝑃 = 0.0 <  0.01 
which is the significance level chosen. This means that the results obtained for the measurements performed 
on EPID (sample E) are better than the ones obtained for the measurements performed on ArcCHECK 
(sample A).  
4.3.2 EPID sensitivity 
One type patient 
In  first part of the fourth study, Study D, the aim was to introduce errors in the XML files in order 
to test the sensitivity of the EPID incorporated on the Edge™ LINAC, i.e., in order to verify if there was 
any relationship between the values of the average gamma and the magnitude of the error introduced. Four 
different types of error were introduced - errors in the MUs (%), errors in the MLC position (mm) (random 
and systematic), and errors in the collimator angle (°). 
 
Initially, the sensitivity of the EPID incorporated on the Edge™ LINAC was tested introducing 
errors in the MUs. For that, a patient plan was chosen (breast patient) and, in the ReadDCMPlan software, 
errors in the MUs with 0 %, 2 %, 4 %, 6 %, -2 %, -4 % and -6 % of magnitude were introduced. 
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In the graphic below, Figure 4.8, we have the composite average gamma values obtained in function 
of the magnitude of error introduced in the MUs, for each counterclockwise (CCW) and clockwise (CW) 
arcs of the plan. 
 
 
Figure 4.8. Composite average gamma values obtained in function of the magnitude error introduced in the MUs, for each 
one of the four arcs of the plan (CCW, CCW2, CW, and CW2). The results were analysed with a 3 %/3 mm gamma criterion. 
Secondly, the sensitivity of EPID was tested introducing systematic errors in the MLC position. For 
that, a patient plan was chosen (head and neck patient) and, in the ReadDCMPlan software, errors in the 
MLC position with 0 mm, 0.5 mm, 1 mm, 2 mm, 3 mm, -0.5 mm, -1 mm, -2 mm, and -3 mm of magnitude 
were introduced. 
 
In the second graphic, Figure 4.9, we have the composite average gamma values obtained in 
function of the magnitude of error introduced in the MLC position, for each counterclockwise (CCW) and 
clockwise (CW) arcs of the plan. 
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Figure 4.9. Composite average gamma values obtained in function of the magnitude systematic error introduced in the MLC 
position, for each one of the four arcs of the plan (CCW, CCW2, CW, and CW2). The results were analysed with a 3 %/3 
mm gamma criterion. 
 
Thirdly, the sensitivity of EPID was tested introducing, this time, random errors in the MLC 
position. For that, a patient plan was chosen (pelvis patient) and, in the ReadDCMPlan software, random 
errors in the MLC position with 0 mm, 1 mm, 2 mm, 3 mm, 4 mm, and 5 mm of magnitude were introduced. 
 
In the next graphic, Figure 4.10, we have the composite average gamma values obtained in function 
of the random magnitude of error introduced in the MLC position, for each counterclockwise (CCW) and 
clockwise (CW) arcs of the plan. 
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Figure 4.10. Composite average gamma values obtained in function of the magnitude random error introduced in the MLC 
position, for each one of the four arcs of the plan (CCW1, CCW2, CW1, and CW2). The results were analysed with a 3 %/3 
mm gamma criterion. 
 
 
Finally, the sensitivity of EPID was tested introducing errors in the collimator angle. For that, a 
patient plan was chosen (brain patient) and, in the ReadDCMPlan software, errors in the collimator angle 
with 3 °, 2 °, 1 °, 0 °, -1 °, -2 ° and -3 ° of magnitude were introduced. 
 
In the next graphic, Figure 4.11, we have the composite average gamma values obtained in function 
of the magnitude of error introduced in the collimator angle, for each counterclockwise (CCW) and 
clockwise (CW) arcs of the plan. 
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Figure 4.11. Composite average gamma values obtained in function of the error magnitude introduced in the collimator 
angle, for each one of the four arcs of the plan (CCW, CCW2, CW, and CW2). The results were analysed with a 3 %/3 mm 
gamma criterion. 
 
From the analysis of Figure 4.8, Figure 4.9, Figure 4.10, and Figure 4.11, we conclude that EPID 
is sensitive to the different types of error introduced once, has we increase the magnitude of the type of error 
introduced, we get higher and higher values for the average gamma, meaning that the irradiation is worse. 
Also, in Figure 4.8, Figure 4.9, and Figure 4.11, we note some asymmetry that may be related to the fact 
that the calibration is not perfect and has some tendency, in this case, to the right, and, therefore, as we 
increase the magnitude of the errors introduced, that asymmetry becomes even more clear. This asymmetry 
is suggesting that we are giving systematically underdose. 
Different types of patient 
The second part of the fourth study, Study D, aimed to introduce errors in the XML files with the 
patient plans in order to test the sensitivity of the EPID incorporated on the Edge™ LINAC, and compare 
the results obtained for the different patient plans, and for each type of error introduced. Three different 
types of error were introduced - errors in the MUs (%), errors in the MLC position (mm) (systematic), and 
errors in the collimator angle (°). 
 
Initially, the sensitivity of the EPID incorporated on the Edge™ LINAC was tested introducing 
errors in the MUs, and comparing the results for seven different patients. Errors in the MUs with 0 %, 2 %, 
4 %, 6 %, -2 %, -4 % and -6 % of magnitude were introduced. 
 
In the graphic below, Figure 4.12, we have the composite average gamma values obtained in 
function of the magnitude of error introduced in the MUs, for each different type of patient.  
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Figure 4.12. Composite average gamma values obtained in function of the magnitude error introduced in the MUs, for 
different types of patient, and for the (a) CCW arc, (b) CCW2 arc, (c) CW arc, and (d) CW2 arc. The results were analysed 
with a 3 %/3 mm gamma criterion. 
 
Secondly, the sensitivity of the EPID incorporated on the Edge™ LINAC was tested introducing 
errors in the MLC position, and comparing the results for nine different patients. Errors in the MLC position 
with 0 mm, 0.5 mm, 1 mm, 2 mm, 3 mm, -0.5 mm, -1 mm, -2 mm, and -3 mm of magnitude were introduced.  
 
In the next graphic, Figure 4.13, we have the composite average gamma values obtained in function 
of the magnitude of error introduced in the MLC position, for each different type of patient. 
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Figure 4.13. Composite average gamma values obtained in function of the magnitude error introduced in the MLC position, 
for different types of patient, and for the (a) CCW arc, (b) CCW2 arc, (c) CW arc, and (d) CW2 arc. The results were 
analysed with a 3 %/3 mm gamma criterion. 
 
 
Finally, the sensitivity of the EPID incorporated on the Edge™ LINAC was tested introducing errors 
in the collimator angle, and comparing the results for five different patients. Errors in the MLC position 
with 6 °, 4 °, 2 °, 0 °, -2 °, -4 ° and -6 ° of magnitude were introduced. 
 
In the next graphic, Figure 4.14, we have the composite average gamma values obtained in function 
of the magnitude of error introduced in the collimator angle, for each different type of patient. 
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Figure 4.14. Composite average gamma values obtained in function of the magnitude error introduced in the collimator 
angle, for different types of patient, and for the (a) CCW arc, (b) CCW2 arc, (c) CW arc, and (d) CW2 arc. The results were 
analysed with a 3 %/3 mm gamma criterion. 
 
From the analysis of Figure 4.12, Figure 4.13, and Figure 4.14, we can conclude once more that 
EPID is sensitive to the different types of error introduced (as we increase the magnitude of the type of error 
introduced, we get higher and higher values for the average gamma, meaning that the irradiation is worse). 
Also, the sensitivity behavior of EPID is pretty similar when considering different types of patient. This is 
crucial once it shows the stability of EPID. 
 
4.3.3 EPID vs ArcCHECK sensitivity 
The sixth study, Study E, aimed to introduce errors in the XML files in order to test the sensitivity 
of both EPID and ArcCHECK. Four different types of error were introduced - errors in the MUs (%), errors 
in the MLC position (mm) (random and systematic), and errors in the collimator angle (°) – in four different 
chosen patients.  
 
Initially, the sensitivity of both systems was tested introducing errors in the MUs. For that, a patient 
plan was chosen (thorax patient) and, in the ReadDCMPlan software, errors in the MUs with 0 %, 2 %, 4 
%, 6 %, -2 %, -4 % and -6 % of magnitude were introduced. 
 
In the graphic below, Figure 4.15, we have the gamma passing rate values obtained in function of 
the magnitude of error introduced in the MUs. 
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Figure 4.15. Composite gamma passing rate values obtained in function of the magnitude error introduced in the MUs. The 
results were analysed with a 3 %/3 mm gamma criterion. 
 
 
Secondly, the sensitivity of EPID was tested introducing errors in the MLC position. For that, a 
patient plan was chosen (head and neck patient) and, in the ReadDCMPlan software, errors in the MLC 
position with 0 mm, 0.2 mm, 0.5 mm, 1 mm, 2 mm, -0.2 mm, -0.5 mm, -1 mm, and -2 mm of magnitude 
were introduced. 
 
In the second graphic, Figure 4.16, we have the gamma passing rate values obtained in function of 
the magnitude of error introduced in the MLC position. 
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Figure 4.16. Composite gamma passing rate values obtained in function of the magnitude error introduced in the MLC 
position. The results were analysed with a 3 %/3 mm gamma criterion. 
 
Thirdly, the sensitivity of EPID was tested introducing, this time, random errors in the MLC 
position. For that, a patient plan was chosen (pelvis patient) and, in the ReadDCMPlan software, random 
errors in the MLC position with 0 mm, 1 mm, 2 mm, 3 mm, 4 mm, and 5 mm of magnitude were introduced. 
 
In the next graphic, Figure 4.17, we have the gamma passing rate values obtained in function of the 
random magnitude of error introduced in the MLC position. 
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Figure 4.17. Composite gamma passing rate values obtained in function of the random magnitude error introduced in the 
MLC position. The results were analysed with a 3 %/3 mm gamma criterion. 
 
Finally, the sensitivity of EPID was tested introducing errors in the collimator angle. For that, a 
patient plan was chosen (brain patient) and, in the ReadDCMPlan software, errors in the collimator angle 
with 6 °, 4 °, 2 °, 0 °, -2 °, -4 ° and -6 ° of magnitude were introduced. 
 
In the next graphic, Figure 4.18, we have the gamma passing rate values obtained in function of the 
magnitude of error introduced in the collimator angle. 
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Figure 4.18. Composite gamma passing rate values obtained in function of the error magnitude introduced in the collimator 
angle. The results were analysed with a 3 %/3 mm gamma criterion. 
 
From the analysis of Figure 4.15 and Figure 4.16, we conclude that, in general, for positive 
magnitude errors introduced, we have higher gamma passing rate values for EPID, while, for negative 
magnitude errors introduced, we have higher gamma passing rate values for ArcCHECK. Looking for all 
the graphics (Figure 4.15, Figure 4.16, Figure 4.17, and Figure 4.18) we conclude that, for positive 
magnitude errors introduced, we have higher gamma passing rate values for EPID. Also, in general, as noted 
before, we can see some asymmetry that may be related to the fact that the calibration is not perfect and has 
some tendency, once again, to the right. 
 
In general, it seems that EPID is as sensitive as ArcCHECK and, besides that, shows more coherent 
results, i.e., the results obtained for EPID are more symmetric (when looking for the same magnitude error 
with different signals) than the ones obtained for ArcCHECK. 
 
It is important to note that, besides the “strangeness” of the different behavior verified between 
EPID and ArcCHECK, this was already noted in previous studies. However, the question hadn’t been 
properly answered yet, and the best hypothesis point out towards the LINAC MLC. 
 
4.3.4 Effects in the organs at risk (OARs) 
Finally, the aim of the last study was to introduce errors in the XML files and export these plans 
into the ARIA® interface in order to compare the plans with errors with the ones without errors and, 
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therefore, verify the effect of the errors in the organs at risk. In this study, 1 patient plan (breast plan) of the 
7 patient plans that were irradiated on the Edge™ LINAC, was analysed to make a comparison between the 
plan with errors and the plan without errors. 
 
In an initial phase, the principal organs at risk were selected, and its dose constraints checked. Then, 
using the External Beam Planning software, the dose volume histograms (DVHs) for each organ at risk 
selected were analysed. Finally, the volume difference between the reference volume (with zero error) and 
the volume verified was calculated for each magnitude error, and the graphics regarding this difference, 
were obtained. 
 
In the graphic below, Figure 4.19, we have the volume difference obtained as function of the gamma 
passing rate, for each magnitude error introduced. These results concern the principal organ at risk – the left 
lung – and were obtained after irradiation with EPID. 
 
 
Figure 4.19. Volume difference values in the left lung obtained in function of the gamma passing rate obtained for each error 
magnitude introduced, and for three different thresholds (1 %/1 mm, 2 %/2 mm e 3 %/3 mm), after irradiation with EPID.  
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In the second graphic, Figure 4.20, we have the volume difference obtained in function of the 
gamma passing rate, separated by type of error. These results concern the principal organ at risk – the left 
lung – and were obtained after irradiation with EPID. 
 
 
Figure 4.20. Volume difference values in the left lung obtained in function of the gamma passing rate obtained. The values 
shown are separated by type of error, and were obtained for the 3 %/3 mm threshold, after irradiation with EPID. 
  
In the next graphic, Figure 4.21, we have the volume difference obtained in function of the gamma 
passing rate, for each magnitude of error introduced. These results concern the principal organ at risk – the 
left lung – and were obtained after irradiation with ArcCHECK. 
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Figure 4.21. Volume difference values in the left lung obtained in function of the gamma passing rate obtained for each error 
magnitude introduced, and for three different thresholds (1 %/1 mm, 2 %/2 mm e 3 %/3 mm), after irradiation with 
ArcCHECK. 
 
In the fourth graphic, Figure 4.22, we have the volume difference obtained in function of the gamma 
passing rate, separated by type of error. These results concern the principal organ at risk – the left lung – 
and were obtained after irradiation with ArcCHECK. 
 
 
Figure 4.22. Volume difference values in the left lung obtained in function of the gamma passing rate obtained. The values 
shown are separated by type of error, and were obtained for the 3 %/3 mm threshold, after irradiation with ArcCHECK. 
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In the next graphic, Figure 4.23, we have the volume difference obtained in function of the gamma 
passing rate, for each magnitude of error introduced. This time, the results concern other principal organ at 
risk – the heart – and were obtained after irradiation with EPID. 
 
 
Figure 4.23. Volume difference values in the heart obtained in function of the gamma passing rate obtained for each error 
magnitude introduced, and for three different thresholds (1 %/1 mm, 2 %/2 mm e 3 %/3 mm), after irradiation with EPID. 
 
In the sixth graphic, Figure 4.24, we have the volume difference obtained in function of the gamma 
passing rate, separated by type of error. These results concern other organ at risk – the heart – and were 
obtained after irradiation with EPID. 
 
Figure 4.24. Volume difference values in the heart obtained in function of the gamma passing rate obtained. The values 
shown are separated by type of error, and were obtained for the 3 %/3 mm threshold, after irradiation with EPID. 
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In the next graphic, Figure 4.25, we have the volume difference obtained in function of the gamma 
passing rate, for each magnitude of error introduced. Once more, the results concern one of the principal 
organs at risk – the heart – and were obtained after irradiation with ArcCHECK. 
 
 
Figure 4.25. Volume difference values in the heart obtained in function of the gamma passing rate obtained for each error 
magnitude introduced, and for three different thresholds (1%/1 mm, 2%/2 mm e 3%/3 mm), after irradiation with 
ArcCHECK. 
 
In the final graphic, Figure 4.26, we have the volume difference obtained in function of the gamma 
passing rate, separated by type of error. These results concern other organ at risk – the heart – and were 
obtained after irradiation with ArcCHECK. 
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Figure 4.26. Volume difference values in the heart obtained in function of the gamma passing rate obtained. The values 
shown are separated by type of error, and were obtained for the 3 %/3 mm threshold, after irradiation with ArcCHECK. 
  
Regarding the Figure 4.19, Figure 4.21, Figure 4.23, and Figure 4.25, we can conclude that the 
results agree with the expected once, as we increase the magnitude error introduced, we have higher volume 
difference values and, therefore, lower gamma passing rate values. In this way, we can conclude that as we 
increase the magnitude of error introduced, we have higher effects in the organs at risk. 
 
Looking for Figure 4.20, Figure 4.22, Figure 4.24, and Figure 4.26, we can conclude that, for both 
EPID and ArcCHECK, we have similar behaviors for the different types of error introduced. Once more we 
see the relation that shows the clinical relevance of the gamma passing rate – as we increase the magnitude 
of the error introduced, we have higher effects in the organs at risk. 
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CHAPTER 5. CLINICAL INTRODUCTION 
By the end of the project (June 2017), given the good results obtained, EPID started to be used 
routinely in the clinic. For that, some studies were made in order to choose the best parameters to use, 
namely the gamma passing rate threshold, the SSD distance (distance between EPID and the source) and 
the values of reference (mean or composite values). 
 
In the next graphic, Figure 5.1, we see the gamma passing rate values obtained for the composite 
image, after performing pre-treatment patient-specific QA with ArcCHECK, against the gamma passing 
rate values obtained after performing pre-treatment patient-specific QA with EPID, for four different 
thresholds. All measurements were made on the TrueBeam™ LINAC. 
 
 
Figure 5.1. Composite gamma passing rate values obtained after performing pre-treatment patient-specific QA with 
ArcCHECK, against the gamma passing rate values obtained after performing pre-treatment patient-specific QA with 
EPID, on the TrueBeam™ LINAC, for (a) a 2 %/2 mm threshold, (b) a 2 %/1 mm threshold, (c) a 3 %/3 mm threshold and 
(d) a 3 %/1 mm threshold. The red line corresponds to the 90 % threshold, while the orange line corresponds to the 95 % 
threshold. 
 
In the next graphic, Figure 5.2, we see the gamma passing rate values obtained for the composite 
image, after performing pre-treatment patient-specific QA with EPID at a distance of 100 cm from the 
source, against the gamma passing rate values obtained after performing pre-treatment patient-specific QA 
with EPID at a distance of 140 cm from the source, on the Edge™ LINAC. 
 
  
80 
 
Figure 5.2. Composite gamma passing rate values obtained after performing pre-treatment patient-specific QA with EPID 
at a distance of 100 cm from the source, against the composite gamma passing rate values obtained after performing pre-
treatment patient-specific QA with EPID at a distance of 140 cm, on the Edge™ LINAC.  
 
 
In the next graphic, Figure 5.3, we see the composite gamma passing rate values, against the mean 
gamma passing rate values, obtained after performing pre-treatment patient-specific QA with EPID, on the 
Edge™ LINAC. 
 
 
Figure 5.3. Composite and mean gamma passing rate values obtained after performing pre-treatment patient-specific QA 
with EPID for a (a) 2 %/2 mm threshold and for a (b) 3 %/3 mm threshold. The orange line corresponds to the 95 % 
threshold. 
 
 
In the graphic bellow, Figure 5.4, we see the (a) composite and the (b) mean gamma passing rate 
values obtained for the 2 %/2 mm threshold, against the (a) composite and the (b) mean gamma passing rate 
values obtained for the 3 %/3 mm threshold, obtained after performing pre-treatment patient-specific QA 
with EPID, on the Edge™ LINAC. 
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Figure 5.4. (a) Composite and (b) mean gamma passing rate values obtained after performing pre-treatment patient-specific 
QA with EPID for two different thresholds (2 %/2 mm and 3 %/3 mm). The orange line corresponds to the 95 % threshold. 
 
In the last graphic, Figure 5.5, we see the gamma passing rate values obtained for the composite 
image, after performing pre-treatment patient-specific QA with ArcCHECK, against the gamma passing 
rate values obtained after performing pre-treatment patient-specific QA with EPID, for (a) a 2 %/2 mm 
threshold, (b) a 2 %/1 mm threshold, (c) a 3 %/3 mm threshold, and (d) a 3 %/1 mm threshold. All 
measurements were made on the Edge™ LINAC. 
 
 
Figure 5.5. Composite gamma passing rate values obtained after performing pre-treatment patient-specific QA with 
ArcCHECK vs EPID for (a) a 2 %/2 mm threshold, (b) a 2 %/1 mm threshold, (c) a 3 %/3 mm threshold, and (d) a 3 %/ 1 
mm threshold. The red line corresponds to the 90 % threshold, while the orange line corresponds to the 95 % threshold. 
 
  
82 
Looking to Figure 5.1, it seems that the 2 %/2 mm threshold 90 % (orange line) is the best threshold 
once it’s the threshold that allows a better ration between the patient plans accepted/rejected. Anyway, once 
we have decided to start using EPID first only on the Edge™ LINAC (given the not so good results obtained 
regarding the comparison ArcCHECK/EPID), the question regarding the best threshold to choose was left 
aside. 
 
According to the results shown in Figure 5.2 we can see that we have higher gamma passing rate 
values when we perform pre-treatment patient-specific QA with EPID at a distance of 140 cm from the 
source. Measuring with EPID at this distance from the source can be a problem once, in the case of having 
a patient plan with big fields, we can exceed the possible irradiation limits and irradiate EPID. For this 
reason, the best option is measuring with EPID at a distance of 100 cm from the source (at the EPID level). 
 
From Figure 5.3, and Figure 5.4, we can conclude that the results are better when we take in 
account the mean gamma passing rate values, and when considering the 3 %/3 mm threshold. However, the 
mean gamma passing rate values are not given automatically by the Portal Dosimetry software and that is 
the reason why we have decided to look for the composite gamma passing rate values (automatically given). 
Also, the higher results obtained for the 3 %/3 mm threshold are not necessarily better because they are so 
high that we cannot distinguish between the different cases analysed. For that reason, once again, we 
concluded that the best choice was the 2 %/2 mm threshold. 
 
Finally, looking for Figure 5.5 we can conclude that the threshold 2 %/2 mm 90 % is the one that 
allows better results (rejects all the patient plans rejected with ArcCHECK, and doesn’t accept practically 
all the other cases as for example the 3 %/3 mm threshold). 
 
To sum up, after analysing the results, we have concluded that the best option was to start measuring 
with EPID first on the Edge™ LINAC and, only after this, on the TrueBeam™ LINAC. The consensual 
recommendations were to measure with EPID at a distance of 100 cm from the source, use the composite 
values for a quantitative analysis (and the mean values of each arc values for a more careful analysis), and 
use the 2 %/2 mm 90 % threshold once this was the more precise one. 
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CHAPTER 6. CONCLUSION AND FUTURE WORK 
With the introduction of advanced irradiation techniques (IMRT and VMAT) in clinical practice, 
as well as with the prescription of more demanding fractionated schemes, where less irradiation fractions 
with higher doses per fraction are considered, the accuracy and feasibility of pre-treatment patient-speciﬁc 
QA procedures gains a higher importance. Thus, it is possible to detect, before the patient treatment session 
starts, human or mechanical errors that could compromise the entire radiotherapy treatment and result in 
serious injuries.  
 
The potential of EPIDs to perform patient-speciﬁc QA has been largely explored due its high 
resolution and automated acquisition of portal images. In this thesis, initial tests for the implementation of 
pre-treatment patient-speciﬁc QA with EPID were performed, on both Varian LINAC (TrueBeam™ and 
Edge™) available in the Radiotherapy Department of Champalimaud Foundation.  
 
Regarding the first study, Study A, were the aim was to compare the gamma passing rates values 
obtained when performing pre-treatment patient-specific QA with ArcCHECK and with EPID, on the 
TrueBeam™ LINAC, we can conclude that we have better results with ArcCHECK, and for the thorax 
patients. While the first realization hasn’t too much to explain, the second realization can be easily explained 
by the size of the fields once, for thorax patients, we usually have bigger fields than for pelvis patients, 
resulting in a worse irradiation of the thorax patients (worse results). Another strong hypothesis would be 
the Portal Dosimetry algorithm calibrated incorrectly. 
 
In the second study, Study B, which aimed to compare the average gamma values, as well as the 
average dose difference values, obtained when performing pre-treatment patient-specific QA with EPID, 
for two different LINACs, we have better results for the average gamma, for both thorax and pelvis patients, 
on the Edge™ LINAC, and better results for the average dose difference, for both thorax and pelvis patients, 
on the Edge™ LINAC. This can be explained by the different a-Si EPIDs incorporated on the two LINACs 
– the Edge™ LINAC has probably a better EPID than the TrueBeam™ LINAC.  
 
Taking in account the third study, Study C, where the aim was, like the first study, to compare the 
gamma passing rates values obtained when performing pre-treatment patient-specific QA with ArcCHECK 
and with EPID, on the Edge™ LINAC, we have obtained better results with EPID, and for the thorax 
patients, lungs mainly. Once again, this can be explained by the size of the fields once, for thorax patients, 
we usually have bigger fields than for pelvis patients. 
 
In the fourth study, Study D, the aim was to introduce errors in the XML files with the patient plans 
in order to test the sensitivity of the EPID incorporated on the Edge™ LINAC. For that, different types of 
error were introduced (MUs, MLC position - random and systematic -, and collimator angle). Given the 
results obtained, we can conclude that EPID is sensitive to the different types of error introduced (as we 
increase the magnitude of the type of error introduced, we get higher and higher values for the average 
gamma, meaning that the irradiation is worse) and that there is some asymmetry that may be related to the 
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fact that the calibration is not perfect and has some right tendency, in this case, to the right, and, therefore, 
as we increase the magnitude of the errors introduced (underdose). 
 
The fifth study, Study E, aimed to introduce errors in the XML files in order to test the sensitivity 
of both EPID and ArcCHECK. After performing the measurements, we concluded that, in general, for 
positive magnitude errors introduced, we have higher gamma passing rate values for EPID, while, for 
negative magnitude errors introduced, we have higher gamma passing rate values for ArcCHECK. These 
results suggest, on the one hand, that EPID is as sensitive as ArcCHECK and, on the other hand, that EPID 
shows more coherent results (more symmetric results). 
 
Finally, the aim of the sixth and last study, Study F, was to introduce errors in the XML files and 
export the plans with errors into the ARIA® interface in order to compare the plans with errors with the 
ones without errors and, therefore, see the effect of the errors in the organs at risk Regarding the results, we 
can conclude that the obtained is in agreement with the expected once, as we increase the magnitude error 
introduced, we have higher volume difference values and, therefore, lower gamma passing rate values, 
meaning that we have higher effects in the organs at risk. Also, for both EPID and ArcCHECK, we have 
similar behaviors for the different types of error introduced, traducing the clinical relevance of the gamma 
passing rate. 
In the end, the analysis of the results shown that EPID, at the same time, allows better results, and 
is more sensitivity than ArcCHECK. Besides that, a crucial point differs the two systems – the time 
dispended performing doing pre-treatment patient-specific QA with EPID is much shorter than the time 
performing doing pre-treatment patient-specific QA with ArcCHECK. However, more clinical cases, 
considering several treatment sites and with diﬀerent fractionation schemes, should be studied with both 
portal dosimetry and ArcCHECK to verify the obtained results. Said that, the results obtained were very 
promising and, for the first time at the clinic, due to the results obtained and proved, EPID had started to be 
used routinely in pre-treatment patient-specific QA in one of the Varian LINAC available (Edge™). 
Therefore, this only encourages the continuation of the study for implementation of pre-treatment patient-
speciﬁc QA with EPID on the Varian TrueBeam™ LINAC, as well as the implementation of in vivo patient-
specific QA. 
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